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CHEMICAL PROBES FOR PROTEIN α-N-TERMINAL METHYLATION

By Brianna D. Mackie, BS
A dissertation submitted in partial fulfilment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2017
Advisor:
RONG HUANG, PHD
ASSISTANT PROFESSOR, DEPARTMENT OF MEDICINAL CHEMISTRY

While protein α-N-terminal methylation has been known for nearly four decades
since it was first uncovered on bacteria ribosomal proteins L33, the function of this
modification is still not entirely understood. Recent discoveries have demonstrated αN-terminal methylation is essential to stabilize the interactions between regulator
of chromosome condensation 1 (RCC1) and chromatin during mitosis, to localize
and enhance the interaction of centromere proteins (CENPs) with chromatin, and
to facilitate the recruitment of DNA damage-binding protein 2 (DDB2) to DNA
damage foci. Identification of N-terminal methyltransferase 1 (NTMT1) unveiled the
eukaryotic methylation writer for protein α-N-termini. In addition, NTMT2 that shares over
50% sequence similarity, has been identified as another mammalian protein α-N-terminal
methylation writer. Knockdown of NTMT1 results in mitotic defects and sensitizes

chemotherapeutic agents in breast cancer cell lines, while NTMT1 knockout mice showed
premature aging. Additionally, NTMT1 has been shown to be overexpressed in a
colorectal and melanoma tumor tissues, and in lung and liver cancer cell lines.
Given the vast array of clinical relevance, chemical probes and inhibitors for
NTMT1 are vital to elucidate information about the function and downstream process of
protein α-N-terminal methylation. Therefore, 47 peptidomimetic compounds have been
synthesized that target NTMT1. These peptide-based compounds range from three to six
amino acids in length and the top 5 compounds have 3- to 300- fold selectivity for NTMT1
compared to other methyltransferases. An inhibition mechanism study has also been
performed to verify the inhibitors are targeting the NTMT1 peptide binding site. Seven
compounds have an IC50 of less than 5 µM and our top inhibitor, BM-47, has an IC50 of
0.32 µM ± 0.06 for NTMT1.
To further elucidate information about the NTMTs and their downstream effects,
we utilized photoaffinity probes to target these enzymes. Our 6 photoaffinity probes
exhibited in a dose- and time-dependent manner. Probe labeling has been shown to be
driven by recognition and selectively and competitively label the NTMT writers in a
complex cellular mixture.

Our results also provided the first indication of substrate

preferences among NTMT1/2. Methylated photoaffinity probes were also synthesized to
identify novel proteins that recognize a methylated N-terminus and shed light on the
function of α-N-terminal methylation.

1. Introduction

Protein modifications may occur post- or co-translationally on the side chains, Ctermini and backbone N-termini of proteins. These modifications are vital in downstream
processes including gene expression, protein degradation, cell signaling and much
more.1,2 Modifications on the side chains have drawn extensive attention as sites for novel
therapeutic targets. In addition, a variety of α-N-terminal modifications including
methylation, acetylation, propionylation, myristoylation, palmitoyation, ubiquitylation and
formylation expose emerging interest. For most N-terminal modifications, the initial Met
must first be cleaved by Met aminopeptidases and then subject to post-translational
modifications by writers; however, α-N-terminal acetylation can occur on the first Met and
α-N-terminal formylation is known to exclusively modify the first Met residue.2–5
Enzymes that catalyze the addition of a covalent modification onto its target are
termed writers. Conversely, proteins that catalyze the removal of that modification are
named erasers. Additionally, proteins that bind to these newly modified proteins are called
readers. Until now, the only known eraser is for N-terminal formylation and there is sparse
information about reader proteins that recognize α-N-terminal modifications. Therefore,
we will focus on the writers for α-N-terminal modifications, which are summarized in
Figure 1.
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Figure 1. Modifications made by writers to the α-N-terminus
The N-terminal acetyltransferase (NAT) family is the writer that catalyzes the
addition of an acetyl group onto the α-N-terminus.4 The NAT family also acts as an Nterminal propionyltransferase (NPT) and catalyzes the addition of a propionyl group,
although this modification is much less common.6 Another newly discovered family is Nterminal methyltransferases (NTMTs), which adds a methyl group onto the α-N-terminus.7
Less common modifications include N-terminal palmitoylation catalyzed by Hedgehog
acyltransferase (HHAT)8 and N-terminal myristoylation carried out by N-terminal
myristoyltransferases (NMTs).9 N-terminal formylation occurs only on Met residues to
indicate the initiation of protein synthesis and is catalyzed by methionyl-tRNA
formyltransferase (FMT).5 Lastly, N-terminal ubiquitylation has also been found to occur
on Lys-deficient proteins by ubiquitin ligase.10 For α-N-terminal modifications, the initial
amino acid sequence determines the types of modifications that can occur (Table 1). The
2

substrate preferences between the NAT family members varies greatly. NatA acetylates
proteins beginning with smaller amino acids like Ala, Cys, Gly, Ser, Thr and Val11,12 while
the NatA catalytic subunit, Naa10, recognizes acidic amino acids like Asp and Glu.13 NatB
recognizes the initial Met residue followed by Asp, Glu, Asn, or Gln,11,14,15 while NatC
recognizes Met followed by a hydrophobic amino acid.11,15,16 NatD has only been found
to acetylate two substrates, H2A and H4 proteins, both starting with Ser-Gly-Arg-Gly.17,18
NatE substrate preference is similar to NatC and will acetylate proteins beginning with
Met followed by a hydrophobic residue.13 NatF is only found in lower eukaryotes but has
a substrate preference that overlaps with NatC and NatE. 19 NMTs add a myristic fatty
acid chain only to proteins beginning with Gly20 while HHAT adds a palmitic fatty acid
chain to proteins starting with Cys.8 N-terminal ubiquitination can occur on any protein
with an unmodified N-terminus but often occurs on naturally Lys-deficient proteins.10 As
stated above, FMT enzyme only adds a formyl group to N-terminal Met residues.21 Lastly,
NTMT1 and 2 prefer an X-P-K/R (X=A, P, S, G) recognition motif22–24 while a recently
found NTMT3 enzyme has found to methylate one protein in yeast with initial sequence
Gly-Lys.25
Table 1. Recognition motif of α-N-terminal writer proteins3
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1.1 α-N-terminal Acetylation
α-N-terminal acetylation is a co- and posttranslational modification that occurs on
60% of yeast proteins and 80-90% of all human proteins.4,26

This modification is

catalyzed by NATs which are the enzymes that introduce an acetyl group on α-N-termini
of proteins. This modification neutralizes the positive charge on the free amino group. 4
NatA has been shown to undergo an ordered bi-bi kinetic mechanism where the peptide
with the N-terminus to be modified binds to the NAT enzyme first, followed by the acetyl
donor, Ac-CoA.27–29

The NAT family shares a conserved Ac-CoA binding site that

contains a conserved Glu24 residue, which acts as a general base to deprotonate the Nterminal amine of the protein substrate to facilitate the nucleophilic attack at the carbonyl
position of the Ac-CoA cofactor.27
There are six eukaryotic NAT family enzymes NatA-NatF, which differs in substrate
specificity and subunit composition. Most Nats contain one catalytic subunit and one or
two auxiliary subunits that affect the substrate specificity. NatA, the most widely studied
NAT enzyme, contains a catalytic subunit Naa10 and an auxiliary subunit Naa15. Naa10
also has the ability to acetylate protein substrates without the auxiliary subunit, but differs
in substrate recognition motifs from the NatA complex.13 NatB contains a catalytic subunit
Naa20 and an auxiliary subunit Naa25. NatC is composed of one catalytic subunit Naa30
and two auxiliary subunits Naa35 and Naa38. NatE is composed of one catalytic domain
Naa50 and one NatA complex; however, NatA and NatE have a different substrate
specificity.30 NatD and NatF only contain the catalytic subunits Naa40 and Naa60,
respectively. The varying recognition motifs of the six NAT enzymes are shown in Table
2. Most NATs are associated with ribosomes, but NatF is associated with the cytosolic
4

side of Golgi and exhibits selectivity for membrane proteins. It is noted that the catalytic
subunits of NatA and NatE have also been found to act as Lys acetyltransferases (KATs)
and N-terminal propionyltransferases (NPTs) in vitro.6,31
Table 2. Summary of the structural subunits, recognition motif and crystal structures
of NATs

All the NAT family have a structurally conserved Ac-CoA binding site, which
consists of a conserved fold containing four sequence motifs that is termed the Nacetyltransferase domain.32 The first resolved crystal structure was the human Naa50
which validated the NAT preference for the α-N-terminal amine over Lys side chains. The
crystal structure identified that the Naa50 substrate peptide was bound to the protein
through a series of backbone hydrogen bonds. Additionally, a hydrophobic pocket exists
that forms van der Waals interactions with the initial Met residue, which prevents Naa50
from interacting with any other N-terminal amino acids.28 Then, the NatA complex crystal
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structure indicated the necessity of the auxiliary subunit in modulating catalytic activity
and substrate preference. The auxiliary subunit of NatA, Naa15, contains 13
tetratricopeptide repeat motifs that wrap around and allosterically reconfigure the NatA
catalytic subunit. Without the auxiliary subunit of NatA, key residues in the catalytic core
including Leu22, Glu24, and Tyr26 are displaced and alters the Naa10 recognition motif
to have preference for acidic amino acids like Asp and Glu. The crystal structure of Naa10
in complex with Naa15 shows a significant conformational change in the α1-loop-α2
region of Naa10 compared to the crystal structure of Naa10 alone.13,27 Superimposition
of the crystal structures of NatA and NatE identified Glu35 and Val29 to be the key
residues for their substrate specificity, respectively.33 NatA can acetylate proteins that
start with Ser, Ala, Thr, Gly and Val, but the peptide binding site cannot accommodate a
Met residue. Structural information indicated that the Glu35 residue in the NatA peptide
binding site would not accommodate a Met residue, due to steric hindrances.33
Alternatively, the key residue in NatE is Val29, a smaller and more hydrophobic residue,
which allows Met to bind in this site.28 Mutation of NatA Glu35 to Ala or Val altered NatA
substrate preference and enabled it to catalyze the acetylation of the N-terminal end of a
NatE substrate, Met-Glu.33 Recently, the NatD and NatF crystal structures have also
been resolved.34,35 NatD has the most specific recognition motif and is only known to
acetylate histones H2A and H4, both beginning with a Ser-Gly-Ar-Gly-Lys sequence. The
α1-α2 and β6-β7 loops of NatD orient the histone proteins N-terminus in a specific manner
within the binding site. The peptide binding site of NatD is similar to NatA where it can
only accommodate smaller residues; however, the NatD site is even more restricted than
NatA. While the NatA binding site can accommodate Ser and Thr residues, NatD can
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only accommodate Ser. Additionally, the 3rd position Arg of the histone substrates inserts
into a pocket that is unique to the NatD enzyme. In addition, the N-terminus of NatD
wraps around the catalytic core and stabilizes these interactions, indicating the Nterminus is also required for catalytic activity.34 The crystal structure of NatF revealed
that it is the most catalytically similar to NatE. Both NatE and NatF contain a hydrophobic
pocket, which gives preference to Met at the 1st position. For the 2nd position of its
substrate, NatE prefers a hydrophobic amino acid while NatF acetylates substrates with
charged side chains at the 2nd position. This difference is due to the larger and more
solvent exposed binding site of NatF. Another structural difference between NatE and
NatF is NatF contains a longer β6-β7 loop which mediates dimerization in the absence of
a substrate peptide, which is unique has not been observed in any other member of the
NAT family.35
α-N-terminal acetylation has demonstrated its significance in a variety of
physiological processes like mediating protein complex formation, regulation of protein
degradation, membrane attachment of small GTPases, and prevention of protein
translocation from the cytosol to the endoplasmic reticulum.30,36,37 For many years, it was
hypothesized that proteins with acetylated N-termini are more stable and less susceptible
to N-end rule pathway that governs the rate of protein degradation through recognition of
the N-terminal residue of proteins. However, recent studies also suggest that N-terminal
acetyl groups decrease the half-life for certain proteins through the Doa10 E3 ubiquitin
ligase.4,38 N-terminal acetylation also plays a role in subcellular localization, promotes
proper association of Trm1p-II to the inner nuclear membrane, and prevents protein
targeting to the endoplasmic reticulum secretory pathway.16,39 N-terminal acetylation also
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regulates protein-protein interactions; for example, the tropomyosin-actin complex
formation is dependent upon the N-terminal acetylation of tropomyosin.40,41 Finally, Nterminal acetylation plays a key role in protein folding. N-terminal acetylation of αsynuclein, a key factor in Parkinson’s disease, leads to an increase in helical folding and
a resistance to aggregation.42
In addition, NATs have been implicated in several pathological conditions. Studies
have shown a relationship between the catalytic subunit of NatA and many
neurodegenerative disorders.4, 6, 16,43 In 2011, a S37P mutation in the NatA catalytic
domain impairs its catalytic activity and the complex formation. It is not known which
specific proteins are not acetylated due to this mutation; however, given that N-terminal
acetylation occurs on approximately 80% of all proteins and NatA is one of the major
enzymes which catalyze this modification, many proteins might be affected.

Such

mutation causes lethal X-linked Ogden syndrome, which results in severe mental delays,
fetal death, an aged appearance, craniofacial anomalies, and cardiac arrhythmias for
boys.44 NatA is also vital to prevent Htt aggregation since knockdown of N-terminal
acetylation leads to an increase in aggregation of Huntingtin (Htt), a key protein in
Huntington’s disease.45 NatA coexpression with β-amyloid precursor protein was found
to suppress β-amyloid protein secretion, which generates the main component of amyloid
plaques that are a signature biomarker of Alzheimer’s disease.46 As mentioned above, Nterminal acetylation of α-synuclein has a significant impact on preventing its aggregation,
which is one of the hallmarks of Parkinson’s disease.42 In addition to NATs involvement
in neurodegenerative disorders, the NAT family is also linked to cancer. Naa15, the
auxiliary subunit of NatA, has been found overexpressed in papillary thyroid carcinoma,
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neuroblastomas and gastric cancer.47–49 Elevated Naa10 expression has also occurred
in breast cancer, colorectal cancer, lung cancer, and hepatocellular carcinoma.50–52
Naa10 overexpression is implicated in increased cell proliferation by promoting cells to
pass the cell cycle checkpoints.4,37 In addition, NatB is overexpressed in hepatocellular
carcinoma and plays a vital role in the cell cycle progression. Knockdown of the catalytic
subunit of NatB led to the fraction of cells in the G 0/G1 phase to decrease while the cells
in the G2/M phase to increase. This is an indicator that NatB is critical for cell-cycle
progression.53 Depletion of NatB in HeLa cells exhibited p21 upregulation, cell cycle arrest
and p53 induction. Depletion of NatC in Hela cells reduced cell proliferation, induced p53
expression and p53-dependent cell death.16
The NAT family has shown to be a potential therapeutic target for a variety of
diseases including cancer, Huntingtins disease and Ogden’s syndrome. Therefore, NAT
inhibitors would be very valuable chemical tools to elucidate its functions. Currently, there
are three known NAT bisubstrate inhibitors (Figure 2). Each inhibitor contains the CoA
portion of the Ac-CoA substrate linked to a peptide with amino acids specific for the NatA
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complex, NatA catalytic subunit or NatE catalytic subunit. Inhibitor 1 targets the NatA
complex and contains a peptide portion derived from high mobility group protein A1.

Figure 2. NAT inhibitors and their respective inhibitory activities54
10

Inhibitor 2 targets the catalytic subunit of NatA and incorporates a peptide derived from
γ-actin while inhibitor 3 contains a portion of hnRNP F protein that targets the catalytic
subunit of NatE. Inhibitor 1 has an IC50 of 15 µM, while inhibitors 2 and 3 have Ki values
of 1.6 µM and 8.2 nM, respectively. Additionally, compounds 4 and 5 were synthesized
without the adenosine ring and showed minimum inhibition, signifying that importance of
the adenosine ring. These inhibitors have exhibited the different inhibition profiles for the
NatA complex and the NatA catalytic subunit, which supports that the auxiliary subunit
plays a role in substrate and inhibitor specificity.54
1.2 α-N-terminal Propionylation
There are approximately 18 proteins that have been identified and verified to be
propionylated at their α-N-termini in vivo.6,55,56 Among them, 10 proteins carry the
recognition motif that may be acetylated by either NatA, NatB or NatD based on the intial
sequence. Additionally, both catalytic subunits of NatA and NatE have been found to
catalyze the addition of a propionyl group from Prop-CoA onto the N-terminus of NatA
and NatE substrates. Therefore, it is believed that the NAT family should be capable of
propionylation.6
Compared with N-terminal acetylation that occurs on 80-90% of human proteins,
propionylation on the N-terminus is less frequent, although the predicted amount of Nterminal propionylation is between 5 to 20%.6 This severe disparity may result from the
low availability of Prop-CoA, which is almost 20 times lower than the cellular concentration
of Ac-CoA (3-30 µM).57,58 To investigate if the ratio of Ac-CoA/Prop-CoA is a key factor
to dictate the predominant acetylation on the N-terminus, kinetic studies were carried out
with three representative NatA substrate peptides. NatA introduced both acetylation and
11

propionylation on α-N termini of all three peptide substrates; however, the amount of
acetylation ranged 3- to 20-fold higher compared to propionylation.6 Although the kcat for
Ac-CoA and Prop-CoA were similar at 0.78 min-1 and 0.70 min-1, respectively, the Km
values for Ac-CoA (Km=18 μM) was about 3-fold lower than Prop-CoA (Km=43 μM).6
These kinetic differences validate that the scarcity of N-terminal propionylation is due to
the low availability of Prop-CoA. Although the function of propionylation is not defined yet,
propionylation does increase bulkiness and hydrophobicity with the addition of an extra
methylene group as compared to acetylation. This modification may alter its ability to
interact with proteins and vary downstream effects.59
1.3 α-N-terminal Myristoylation
Although myristic acid is reported to be less than 1% of the total fatty acid in cells,60
and only 0.5% of proteins in the cell are N-terminally myristoylated,61,62 myristoylation has
a wide array of relevance and function among posttranscriptional modifications for
proteins. Proteins actin, gelsolin and p21-activated kinase 2 (PAK2) are N-terminally
myristoylated post-translationally following cleavage of caspase-3, which leads to the upregulation of apoptosis.9 Additionally, the co-translational myristoylation of Gα-protein
assists in plasma membrane targeting and G-protein signaling.63 N-Myristoyltransferase
(NMT) is an enzyme that catalyzes the transfer of myristic acid from myristoyl-CoA, a 14carbon fatty acid, to the N-terminal Gly residue of its substrates. NMT is a cytosolic
monomeric enzyme that is present only in eukaryotes and not prokaryotes.64,65 NMT plays
a vital role in subcellular localization, protein folding, and enhancing hydrophobicity to
increase protein-protein and protein-membrane interactions.66–68 Studies have also
confirmed that myristoylation is able to initiate the first step of the protein maturation
12

process and other conformational changes when in combination with either Ca2+ binding
or phosphorylation.69,70
NMT is a part of the GCN5 acetyltransferase superfamily of proteins and is present
as two forms, NMT-1 and NMT-2.71 NMT-1 exists as four different isoforms, ranging in
molecular weight from 49-69 kDa, while only one form of NMT-2 has been reported at 65
kDa.72 NMT-1 has been shown to be vital for vegetative cell growth while knockdown of
NMT-1 inhibits tumor progression.73,74 NMT-2 has not been as extensively studied;
however, elevated levels of NMT-2 are found in colorectal cancer and human brain
tissues.75,76 The NMT crystal structure (PDB 2NMT, 2.9Å) contains a characteristic
symmetric two-fold saddle-shaped β sheets bordered by α helices. The two binding sites
of NMT are the myristoyl-CoA binding site, located in the N-terminal half of the enzyme,
and the peptide binding site formed at the C-terminal half.77

Figure 3. NMT ordered bi-bi catalytic cycle78
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The NMT family undergoes an ordered bi-bi kinetic mechanism. For proteins to
undergo myristoylation, a two-step process must occur (Figure 3). The myristoyl-CoA
substrate binds to NMT first, followed by the N-terminal Gly peptide substrate. Catalysis
may then occur producing an N-myristoylated peptide.79–81 There are many confirmed
NMT substrates including various Tyr kinases, nitric oxide synthase, the α subunits of
heterotrimeric G-proteins, and many virus proteins including HIV-1.64,82 A series of
peptides originating from the N-terminal sequence of NMT substrates were synthesized
and kinetically evaluated against NMT.

The peptide substrates had Km values which

ranged from 16 µM-100 µM while myristoyl-CoA had a Km value of 5.8 µM.71 A summary
of the kinetic parameters of the NMT substrates are shown in Table 3.
Table 3. Kinetic parameters of recombinant NMT from bovine cardiac muscle71

NMT has been identified as a promising target in many therapeutic areas including
anticancer, antifungal and antiparasitic. NMT-1 is a confirmed biomarker for the detection
of breast, ovarian, lung and colon cancer.83,84 Additionally, NMT has shown elevated
activity in adenocarcinoma and gallbladder cancer.84–86 NMT is also an antifungal target
due to its vital role in the eukaryotic cell. Experiments show that many species of fungi
cannot survive without NMT.87 NMT is a single-copy gene in protozoan parasites and
many NMTs from these parasites have been identified as valid drug targets. 88,89 NMT
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exists in the human parasite P. falciparum, a primary agent in malaria, and inhibition of
NMT lead to failure of the assembly of the inner membrane which is critical for the
parasitic life cycle.89,90

Given the wide clinical application potential of NMT, NMT

inhibitors have been widely discovered and synthesized.
While over sixty NMT inhibitors have been reported for all three disease areas,
there are many classes of NMT inhibitors for antifungal properties including benzofurans,
peptidomimetics, and benzothiazoles. Two benzofuran derivatives, compounds 6 and 7,
showed IC50 values of 0.39 nM against C. alicans NMT,91,92 while peptidomimetic
inhibitors have yet to show in vivo antifungal activity due to poor membrane permeability.
The most potent inhibitor to date, compound 8, is a pyrazole sulfonamide antiparasitic
with an IC50 value of 3 nM against human NMT.93 This drug cured mouse models with
stage 1 infection of T. brucei and T. brucei rhodesiense;93 however, it was unable to cross
the blood-brain barrier.94 Recent studies infer the application of NMT inhibitors as novel
anticancer drugs. A benzenesulfonamide inhibitor, compound 9, had an IC50 value of 5
nM against human NMT and inhibited the growth of breast and colon cancer cell lines at
GI50 values of less than 1 μM.95 NMT is an ideal drug target for a variety of clinical fields
and the amount of successful inhibitors discovered reflects that (Figure 4).
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Figure 4. NMT inhibitors and their respective IC50 values78
1.4 α-N-terminal Palmitoylation
The addition of a palmitoyl group (C16) to proteins is important in cellular
localization, protein-protein interactions, protein trafficking and protein stability.96,97 This
modification commonly occurs as S-palmitoylation by attaching a reversible thioester
linkage to the side chain of Cys residues. However, N-palmitoylation occurs when a Cys
residue is at the α-N-terminus of the protein to undergo an S-palmitoylation intermediate
and followed by a chemical rearrangement to yield a more stable N-palmitoylation at the
α-N-terminus. This N-palmitoylation was first discovered after analysis of the secreted
morphogen Sonic Hedgehog.98
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The Sonic Hedgehog (Shh) is a secreted signaling protein that plays significant
roles in the brain during embryonic development.99 Initially, Shh is synthesized as a 45kDa precursor for the secretory pathway, but later undergoes autocleavage which results
in a 19-kDa N-terminal signaling protein (ShhN). ShhN is the only known human protein
that undergoes α-N-palmitoylation.98,100 Therefore, the enzyme that catalyzes this
modification is named the Hedgehog acyltransferase (Hhat). Hhat is a member of the
membrane-bound O-acyl-transferase (MBOAT) family which can be categorized into
three groups based on function. The first group acylates a hydroxy group during neutral
lipid biosynthesis, the second group acylates an amino acid within a protein, and the third
acylates a lysophospholipid for phospholipid remodeling. Hhat falls in the second MBOAT
family group which are enzymes involved in protein acylation.101,102 The palmitoylation
increases hydrophobicity of ShhN, which is essential in the strength of signaling and
generation of a protein gradient in developing embryos. 103 Mice having palmitoylationdeficient ShhN, mutant Hhat or Hhat-knockout showed severe defects in limb
development and neural tube.104
The first biochemical assay performed to verify Hhat specificity for ShhN was
established in 2008.

The mechanism of Hhat is dependent upon the presence of

palmitoyl-CoA, which is 70-80 µM in physiological conditions,105 the substrate donor, and
the availability of a free amino Cys residue. The α-N-palmitoylation did not take place
when the Cys residue was replaced with Ala or Ser residues. It was also found that a
peptide containing an 11-amino acid sequence of the ShhN protein was sufficient for the
palmitoylation to occur in vitro.100 However, in 2012, studies revealed that the first six
amino acids of mature ShhN (CGPGRG) are sufficient for palmitoylation by Hhat and the
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N-terminal Cys amino acid is preferred but can be replaced by Ser. A basic amino acid at
the fifth position is vital, but can be rescued if placed at position 7. 106 Lastly, it was
identified that colocalization of Hhat and Shh occurred in the endoplasmic reticulum and
Golgi.100
All acyltranferases within the MBOAT family have multiple hydrophobic
transmembrane domains which has made the biochemical characterization of these
enzymes difficult.102 Multiple point mutations and truncations of Hhat were performed to
analyze the effect of enzyme activity. Truncations at the N- and C-terminus resulted in
reduced palmitoylation activity and protein stability.107 Additionally, a conserved region
of residues among MBOAT enzymes (residues 196-234) were found to be required for
Hhat activity.107 11 point mutations and 10 deletion mutants were carried out within Hhat,
and the majority had comparable stability as WT Hhat; however, they did cause a loss of
catalytic activity. Two key residues were identified to be critical for catalytic activity or
substrate recognition. Mutation of Asp339 to Ala resulted in a complete loss of WT
activity, indicating this residue is vital for catalytic activity.107 Residue H379 is conserved
among the active site of all MBOAT enzymes and is verified to be critical for catalysis108–
110;

however, a H379A mutation in Hhat only led a 50% reduction in WT Hhat activity.107

This suggests that this His residue may be more critical for recognition and binding of Shh
and not catalytic activity.
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Abnormal Hhat signaling has shown to contribute to the growth of many cancers
including lung squamous cell carcinoma, breast cancer, and the proliferation of pancreatic
cancer cells.111–114 Additionally, Hhat knockdown has also shown to reduce tumor growth
in a pancreatic cancer mouse model supporting Hhat as a promising anticancer target.114
Currently, there are only four known inhibitors for Hhat. High-throughput screening of a
library of 63,885 compounds using an assay that monitors Hhat-mediated Shh
palmitoylation was performed. An additional screen using a cell viability assay was then
executed and led to 95 confirmed hits. The top four compounds named 10, 11, 12, and
13

(Figure
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Figure 5. Hhat inhibitors and their respective IC50 values115
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activity

and

drug-like

properties. Compound 12 was confirmed to demonstrate selective inhibition of Hhat that
blocks Hhat-mediated Shh palmitoylation in cells.115 Thus, inhibitor 12 was selected for
further studies in animal studies, but 12 only had a short half-life of 17 min in vivo. Hhat
inhibition offers a new anticancer target for cancers with Shh overexpression.107,115
1.5 α-N-terminal Ubiquitination
Ubiquitination or ubiquitylation is another common posttranslational modification
that adds a ubiquitin molecule onto substrate proteins. Ubiquitin is a 76 amino acid long,
8.5 kDa regulatory protein.116 Initially, this modification was only known to occur on the
side chains of Lys resides via an isopeptide bond. However, now it is understood that
this modification also occurs on Ser/Thr side chains through an ester bond, Cys residues
through a thioester bond, or on the N-terminus through a peptide bond.117–119 The first
verified protein to be ubiquitinylated on the α-N-terminus was in 1998 on the myogenic
transcriptional switched (MyoD) protein.120 Currently, there are over twenty proteins,
many which are naturally Lys-deficient, that undergo this modification solely on the Nterminus and not on the internal Lys.121–139
Ubiquitination has many functions including subcellular localization, subnuclear
trafficking, DNA damage repair, activation or inactivation or proteins, modulating proteinprotein interactions, and modification of kinases.118,140–142

However, the main role

associated with ubiquitination is as a signal for protease or lysosome degradation in
eukaryotic cells.118,119 The first study to indicate the role of N-terminal ubiquitination in
protein degradation was with the MyoD protein. Nine internal Lys residues exist in the
MyoD protein with the potential to be ubiquitinylated and initiate the signal for degradation.
All nine Lys residues were replaced; however, there was no significant decrease in the
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degradation or conjugation of MyoD in vivo or in vitro. However, when all internal Lys
residues were retained and the N-terminus was carbamaylated, MyoD was stable in vivo
and in vitro.120 This was the first indicator that a protein can be prone to degradation
through ubiquitination on the N-terminus and not through an internal Lys. Proteins that
are susceptible to N-terminal ubiquitination are any proteins that have a free, unmodified
N-terminus.

Approximately 75% off all cellular proteins are N-terminally acetylated;

therefore, the remaining 25% are potential substrates for N-terminal ubiquitination.10
There are many eukaryotic proteins that share the common ubiquitin fold and are
often termed ubiquitin-like proteins. However, many of these proteins are structurally
similar to ubiquitin but do not undergo conjugation to other proteins. 143 Ubiquitin itself is
highly conserved among yeast and humans with only 3 of 76 amino acids varying.144 The
process of ubiquitination requires three different enzyme types. The first enzyme is the
Ub-activating enzyme (E1) that adenylates the ubiquitin C-terminus using energy from
ATP hydrolysis and forms an ubiquitin-adenylate intermediate.145 The C-terminus of
ubiquitin then binds to a Cys residue in E1 through a thioester linkage and releases
AMP.10 The next enzyme involved is an Ub-conjugating enzyme (E2). The ubiquitin
molecule is transferred from E1 to a Cys residue on E2, where there are at least 50 in the
mammalian genome.146,147

Lastly, the E2 enzyme transfers ubiquitin to the protein

substrates with the assistance of an Ub-ligase enzyme (E3). There are hundreds of E3
enzymes and they serve as the substrate recognition enzymes which have the ability to
interact with both E2 and the proteins substrates. This hierarchical cascade permits tight
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regulation of the ubiquitination process (Figure 6).118 This process can be repeated many
times to add additional ubiquitin moieties and create a polyubiquitin chain.148 In few
cases, there are E4 enzymes that add a pre-formed polyubiquitin chain to the protein.149
A target protein must contain a minimum of four linear ubiquitin moieties before it is
recognized by proteases for degradation.150 Although, it is not fully understood why
certain proteins are targeted for degradation.
The last amino acid in the ubiquitin sequence, Gly76, will attach itself to its
protein substrate at the N-terminus or Lys side chain.

If the protein is then

polyubiquitylated, further ubiquitin compounds will link their Gly76 to one of seven

Figure 6. Ubiquitin hierarchal cascade and varying downstream effects119
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possible Lys residues or the N-terminus of the initial ubiquitin moiety.151 The attachment
of the ubiquitin at various Lys residues or N-terminus often indicates varying function for
the target protein. Figure 6 shows the ubiquitination cascade and the varying downstream
roles.119 Once proteins are targeted for degradation, the proteins are swiftly degraded to
smaller peptides and the ubiquitin subunits are cleaved and recycled for later use. 152
The ubiquitin pathway is highly involved in a variety of clinical fields including
neurodegenerative diseases, cancer, viral diseases, and cardiovascular diseases. 153,154
For example, the E3 Ub-ligase, Parkin, is associated with early-onset autosomal
recessive forms of Parkinson’s disease.155 Additionally, another E3 ligase named
HUWE1, is overexpressed in multiple cancer types including breast, lung and colorectal
carcinomas.156 Also, overexpression of MDM2 (HDM2), another E3 ligase, is also present
in breast, lung, glioblastomas, esophageal carcinomas, and malignant melanomas and
promotes the degradation of p53, the guardian of the genome. 157 Given the wide
therapeutic potential of the ubiquitin pathway inhibitors, it is not surprising that a generous
amount of inhibitors have already been discovered. In 2003, Bortezomib was the first
drug approved by the FDA as a proteasome inhibitor for the treatment of refractory
multiple myeloma.158 It was also in clinical trials for diffuse large B cell lymphoma, nonHodgkin’s lymphoma and many other cancers.159 Since then, another proteasome
inhibitor, Carfilzomib, has been approved by the FDA and many other second-generation
proteasome inhibitors are currently being developed.160 Small-molecule inhibitors have
been discovered and developed primarily through high-throughput screening techniques
and have targeted each stage of the ubiquitination cascade. 161
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1.6 α-N-terminal Formylation
N-terminal formylation occurs during protein synthesis of bacteria and
organelles.162 The enzyme methionyl-tRNA formyltransferase (FMT) transfers a formyl
group from 10-formyltetrahydrofolate to the N-terminus of Met residues.21 The formylation
of Met was first discovered in 1964 is now understood to signal the initiation of protein
synthesis.162,163 This reaction occurs in bacteria and organelles,21 and formyl-Met (fMet)
is the first residue that appears from bacterial ribosome. Although N-formylation is
conserved among most bacteria, it is not understood which proteins are dependent upon
this reaction.164,165
A proteomic study was performed to explore how mutations in FMT affects the
metabolic capabilities of bacteria. The results indicated that the folic acid metabolism
was altered after FMT mutation due to increased susceptibility to trimethoprim and
sulfamethoxazole where the MICs were 3.5- and 3-fold lower, respectively.166 The studies
also verified that α-N-terminally formylated peptides are critical for the oxidation of
pyruvate and the FMT mutant consumed glucose less efficiently than FMT wild type.
Finally, it was found that FMT mutant led to a lack of degradation of Arg through the Arg
deiminase pathway,166 which is needed as an ATP source by substrate level
phosphorylation.167 These results elucidated specific pathways that depend on N-terminal
formylation; however, further studies to understand which enzymes rely on this reaction
is required.
The protein synthesis cycle begins with aminoacyl-tRNA synthetase transferring a
Met on to an initiating tRNA. This Met-tRNA product is now susceptible to formylation by
FMT. After the fMet-tRNA complex is formed it is moved to the ribosome in order for the
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protein synthesis to initiate. Next, the formyl group is removed from the initial Met by
peptide deformylase (PDF) and then the Met can also be removed by Met
aminopepdidases.168 This protein synthesis cycle is shown in Figure 7.

Figure 7. Formylation and deformylation cycle for protein synthesis168
While there are no inhibitors for FMT, designing inhibitors for PDF, the enzyme
that catalyzes the removal of the formyl group, has been an attractive strategy. Given
that PDF is present in prokaryotic cells and absent in mammalian cells, it is an ideal
antibiotic target.169,170 Inhibitor 14, a naturally occurring tight-binding PDF inhibitor, has
a Ki value of 0.28 nM.171 Although 14 had poor bioavailability, the discovery of 14 led to
the increase in rational design of inhibitors for PDF.
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A variety of PDF inhibitors have been discovered including peptidic inhibitors and
small molecule inhibitors. These inhibitors have been identified through high-throughput
screening, ligand-based screening and ration drug design.172 One example of a peptidic
inhibitor is compound 15, which was discovered through screening a library of
metalloenzyme compounds.

Compound 15, which has a very similar scaffold as

compound 14, had an IC50 of 7 nM and high selectivity for PDF.173 A small molecule
bicyclic inhibitor, 16, was also discovered through screening and had an IC50 of less than
5 nM and high selectivity for PDF, but had poor antibacterial activity.174 PDF inhibitors
14, 15 and 16 are shown in Figure 8. Inhibitors for PDF has been a verified as a validated
effort given there are currently three compounds in Phase I or Phase II clinical trials. 175–
177

Figure 8. PDF inhibitors and their respective IC50 values173,174
1.7 α-N-terminal Methylation
Protein α-N-terminal methylation has been known for nearly four decades since it
was first uncovered on bacteria ribosomal proteins L33. 178 Subsequent detection of this
modification on histone H2B, cytochrome c-557, and myosin light chain proteins revealed
that α-N-terminal methylation normally occurs on an N-terminal X-P-K (X is A, P, S)
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sequence.179–181 Identification of the eukaryotic N-terminal methyltransferase 1
(NTMT1/NRMT1) unveiled the eukaryotic methylation writers for protein α-N-termini.7,
22,182

Since then, there have been an increasing number of reports of α-N-terminal

methylation detected on new protein substrates such as regulator of chromosome
condensation 1 (RCC1), the tumor suppressor retinoblastoma 1 (RB1), oncoprotein SET
(also known as I2PP2A, TAF1α), damaged DNA-binding protein 2 (DDB2), Poly [ADPribose] polymerase 3 (PARP3), and centromere proteins A and B (CENP-A and CENPB).7,183–187
Protein α-N-terminal methylation was originally proposed to regulate proteinprotein interactions since the methylated proteins initially identified were involved
in large macromolecular complexes.188 Recent discoveries have demonstrated its
relevance in protein-DNA interactions. The α-N-terminal methylation is essential to
stabilize the interactions between RCC1 and chromatin during mitosis, to localize
and enhance the interaction of CENPs with chromatin, and to facilitate the
recruitment of DDB2 to DNA damage foci. 184–187 In addition, the level of α-Nterminal methylation increases in response to a variety of extracellular stimuli,
including increased cell density, heat shock, and arsenite treatment.185,189
In addition to NTMT1, its close homolog NTMT2 that shares over 50% sequence
similarity, has been identified as another mammalian protein α-N-terminal methylation
writer. Studies from Schanar-Tooley et al. indicated that NTMT1 and 2 share the same
X-P-K recognition motif, but suggested that NTMT2 acts as a monomethylase to prime
monomethylated substrates for NTMT1.22 Recent structural studies from us and Li et al.
substantiate that NTMT1 prefers an X-P-K/R (X can be any residue type other than D/E)
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motif.23,24 Although co-crystal structures of NTMT1 in a ternary complex with varying
peptide substrates and SAH are now available, there is scarce knowledge of NTMT2
except the initial report in 2013.22 One reason for the scarcity is the limited stability of
recombinant full-length NTMT2; therefore, no structural information of NTMT2 is currently
available. Recently, a third N-terminal methyltransferase has been discovered in yeast.
Elongation factor methyltransferase 7 (Efm7) has shown to methylate eukaryotic
elongation factor 1A (eEF1A), a protein that delivers aminoacyl-tRNAs to ribosome, in
vitro. Additionally, studies verified that overexpression of Efm7 resulted in an increase in
N-terminal methylation while knockdown resulted in a loss of methylation in vivo.
Interestingly, Efm7 does not target the traditional X-P-K recognition motif and solely
methylates an N-terminal Gly residue and the adjacent Lys. However, the adjacent Lys
is methylated only after the N-terminal Gly is fully saturated. Nonetheless, Efm7 is the
only known methyltransferase that methylates the N-terminus and an adjacent Lys
residue of a single protein. Currently, eEF1A is the only known substrate of Efm7;
however, there are 35 other yeast proteins with a beginning G-K sequence that have the
potential to be substrates.25
Among the N-terminal methyltransferase family, only the structure of NTMT1 has
been extensively studied. NTMT1 is highly conserved from yeast to humans 182 and many
co-crystal structures of NTMT1 in complex with peptide substrates and the cofactor Sadenosyl homocysteine (SAH) have been determined.7,23,24 The crystal structures show
that NTMT1 folds as a single domain and include a Rossman fold that contains sevenstrand β sheets and five α helixes which is common of methyltransferases. However,
NTMT1 also comprises an N-terminal extension containing a 310 helix and two α helixes,
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and a β hairpin inserted between strand β5 and helix α7, which is unique from other
methyltransferases. The crystal structures also revealed that the peptide substrates all
bind in a similar manner through a negatively charged channel connected to the cofactor
S-adenosyl methionine (SAM) binding site. The N-terminal amine of the peptide substrate
is pointing toward the SAM methyl donor.24 This is distinct from other methyltransferase
enzymes, which commonly have their peptide binding site on the surface and only insert
the Lys or Arg side chain to be modified into a narrow channel pointing toward the SAM
binding site.190 The structural information gained from the crystal structure supported the
selectivity NTMT1 has for the N-terminus over free amino side chains.

Homology

modeling of NTMT2 has also been performed and overlayed over the NTMT1 cyrstal
structure (PDB: 2EX4). The NTMT1 crystal structure is shown in green with SAH shown
in blue while the NTMT2 homology model is shown in yellow (Figure 9). The main
distinction between the crystal structure and the model is the N-terminal 60-amino acid
domain of NTMT2, which is not present in NTMT1.
Although the only endogenous substrates verified to be methylated in vivo begin
with S/P/A/G, NTMT1 was found to methylate peptides beginning with F/Y/C/M/K/R/N/Q
and H in vitro.24 The tolerance for a variety of amino acids at the first position of the
substrate can be explained by the spacious binding pocket surrounding the first position
side chain. From the crystal structure, a hydrogen bond is shown between the S1 side
chain and the main chain of Met30 from NTMT1.24 This binding site is large enough to
accommodate bulky aromatic residue Tyr and is substantiated by enzymatic binding
data.24 On the other hand, the negatively charged channel prevents negatively charged
amino acids, like D and E, at the S1 position.7, 24,182 Additionally, a vital hydrogen bond
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Figure 9. Homology model of NTMT2 (yellow) having the same overall fold as NTMT1
crystal structure (green; PDB code 2EX4). SAH molecule in the NTMT1 crystal
structure is shown in blue.22
is found between the carbonyl oxygen of the first residue of the NTMT1 substrate and the
carboxamide side chain of Asn168. Mutation of Asn168 to Lys resulted in a ~36-fold loss
in Km, indicating the importance of this interaction between NTMT1 and its peptide
substrate. The second residue P2 is in a hydrophobic pocket formed by residues Leu31,
Ile37, and Ile214.24

It also forms a stacking interaction with the indole of Trp136.

Mutagenesis of Trp136 or substitution of the Pro to any other amino acid resulted in a
loss of enzymatic activity.24,182 The third residue K3 forms two key hydrogen bonds with
side chains Asp177 and Asp180 of NTMT1. NTMT1 can tolerate Lys or Arg residues at
the third position of the peptide substrate.7, 24,191 All known protein substrates contain the
X-P-K initial sequence besides CENP-A, which contains an X-P-R motif. The amino acids
found at the fourth position of NTMT1 substrates are Arg, Lys and Thr. The fourth residue

30

is adjacent to a negatively charged substrate binding channel.24 The fifth and sixth
residues, such as I5 and A6, only form a few backbone hydrogen bonds with NTMT1.24
NTMT1 catalytic transfer of methyl groups onto protein substrates takes place
through a random-ordered bi-bi kinetic mechanism.192 A ternary complex comprised of
NTMT1, the cofactor SAM, and the protein substrate is formed with either substrate
binding to NTMT1 first.192 The key residues involved are the highly conserved Asp180
and His140 which act as general bases to enable the deprotonation of the α-amino group
of the N-terminus. The deprotonated amino group can then undergo a S N2 reaction and
attack SAM to enable the transfer of the methyl group onto the peptide substrate.
Additionally, crystal structures were also resolved with monomethylated peptide
substrates and they had the same orientation as the unmethylated substrates. 24 These
results support the understanding that NTMT1 follows a distributive mechanism and has
no significant preference for unmethylated or monomethylated substrates. 192
NTMT1 methylates damaged DNA-binding protein 2, which is crucial for DNA
repair.184

Knockdown

of

NTMT1

results

in

mitotic

defects

and

sensitizes

chemotherapeutic agents in breast cancer cell lines like MCF-7 and LCC9, while NTMT1
knockout mice showed premature aging.183,193 Additionally, NTMT1 has been shown to
be overexpressed in a variety of cancer cell lines and patients’ tumor tissues including
colorectal, melanoma, carcinoid, lung and liver according to data from ProteinAtlas. 194
Additionally, methylation of regulator of chromosome condensation 1 (RCC1) is essential
to stabilize its interaction with chromatin throughout mitosis for proper division.185,186
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Given that NTMT1 forms a ternary complex, bisubstrate inhibitors which target
both binding sites have been proven to be an effective strategy to increase selectivity and
potency (Figure 10). This technique has been applied in many enzymes with two binding
sites including histone acetyltransferases (HATs) and protein Arg methyltransferases
(PRMTs).54,195,196 The first generation NTMT1 bisubstrate inhibitor is compound 17. The
NAM portion of this bisubstrate inhibitor is a SAM analog; however, the sulfonium atom
is replaced with a nitrogen to increase stability. The peptide portion of the inhibitor is the
beginning six amino acids of RCC1. There is a triazole linker that was utilized due to its
optimum size in coupling both substrate portions together. This optimum linker size was
determined based on the distance found in docking studies between the sulfonium atom
in SAM and the free amine of the peptide substrate. Through fluoresnce-based assays
and MALDI methylation assays, the IC50 of this compound was found to be 0.81 μM. To
verify specificity of this inhibitor, two other methyltransferases were also tested. Inhibitor

Figure 10. Bisubstrate strategy to inhibit methylation
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17 showed less than 15% inhibition against PRMT1 and less than 50% inhibition against
protein Lys methyltransferase G9a at 50 μM. Lineweaver Burke plots also illustrated that
this inhibitor competes at both sides confirming the bisubstrate strategy was effective. 197
The second generation of bisubstrate inhibitors were also synthesized utilizing alkyl
linkers in replace of the triazole in order to probe varying distances between the substrate
portions. A series of inhibitors were synthesized and the most potent compound, 18, had
a propylene linker and an IC50 of 0.94 μM. Selectivity studies against PRMT1 and G9a
were also carried out and the bisubstrate inhibitor showed no significant inhibition at 30
μM against either enzyme.198 These inhibitors are the first bisubstrate inhibitors which
target NTMT1 (Figure 11).

Figure 11. NTMT1 inhibitors and their respective IC50 values197,198
Bisubstrate inhibitors have been a successful strategy among methyltransferases
given that they typically have higher selectivity and potency for their target. Nevertheless,
bisubstrate inhibitors are often too large, not cell-permeable or drug-like. Therefore, there
is a need for small molecule inhibitors to elucidate information about downstream process
of protein α-N-terminal methylation. While there are many reports that imply the
importance of α-N-terminal methylation, the function of protein α-N-terminal
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methylation is still in its infancy. Little progress has been made in characterizing
the recognition motif and readers responsible for specifically recognizing this
modification and translating it into a biological signal. Lack of such knowledge has
greatly limited our understanding of its functions from a systematic viewpoint.
Given that the NTMT family has two binding sites, a small molecule inhibitor may
target the SAM cofactor binding site or the peptide substrate binding site. Since SAM is
a common cofactor for many methyltransferases, targeting the peptide binding site should
achieve higher selectivity. Therefore, the intention of this project is to design potent and
selective peptide inhibitors for NTMT1. Herein, we report the design and synthesis of the
first series of selective photoaffinity probes for the NTMT family. Additionally, one
approach to identify proteins which write a methyl group onto the N-terminus of proteins
or recognize a methylated N-terminus of proteins is photoaffinity labeling. Photolabeling
targets the active site of a specific protein where the covalent labeling is driven by specific
recognition. A series of unmethylated photoaffinity probes which taget the NTMT family
and a series of methylated photoaffinity pobes which target proteins downstream from the
NTMTs have been synthesized. These photoaffinity probes have sucessfully labeled
spiked-in NTMT1 in a complex cell mixture. Additionally, these probes have revealed
novel information about substrate preferences among NTMT1 and NTMT2. These
photoaffinity probes have the ability to identify information about the function of protein αN-terminal methylation.
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2. Results and Discussion

2.1 NTMT1 Peptidomimetic Inhibitors
2.1.1 Design
The ultimate goal of this project was to develop potent inhibitors that specifically
inhibit NTMTs. Based on our crystal structures, the first amino acid at the N-terminus
mainly interacts with N168 through the carbonyl amide bond and is tolerable towards
NTMT1 recognition, which is substantiated by the wide range of amino acids which exist
at the first position.24 Given the mechanism of methylation, the α-N-terminal amine is
essential to serve as a nucleophile to attack SAM, but it is not critical for binding.
Therefore, we hypothesized that NTMT1 peptidomimetic inhibitors can be developed
through the removal of the N-terminal amine of peptide substrates. We initiated our efforts
by incorporating carboxylic acids onto a tripeptide to mimic the Pro, Gly, Ser, or Tyr at the
first position (Table 4). We also introduced a benzyl group at the first position to explore
the importance of the first amide group.
In addition, we also explored the modifications at the second, third and fourth
position in an attempt to increase inhibitory activity, as well as to enhance stability since
peptide-based inhibitors are susceptible to degradation and peptidases. Pro is known to
undergo ci-trans isomerization. From our crystal structures, Pro has only shown the trans
conformation24; therefore, we hypothesized that the trans conformation is favorable to
interact with NTMT1. Literature has stated that although alpha-methyl-Pro has the ability
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Table 4. Summary of modifications at 1st position for tetramer inhibitors

to exist as a trans or cis conformation, the cis conformation is the overwhelming
majority.199 Therefore, an alpha-methyl-Pro was designed at the 2nd position to lock its
cis conformation and probe inhibition differences with changes at the P2 position. Arg has
been detected at the 3rd or 4th position in NTMT1 substrates, so it was synthesized at
either position to evaluate the inhibitory activity. Likewise, Thr was incorporated at the 4 th
position. Additionally, trimethylated Lys and D-Arg were designed to increase cell
permeability and stability, respectively.200 To investigate the optimal length for inhibitory
activity, we also synthesized one peptidomimetic to mimic tripeptides and five to mimic
hexapeptides.
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2.1.2 Docking Studies
To support our hypothesis and validate the binding mode of our designed
inhibitors, docking studies of the inhibitors were performed using the NTMT1 co-crystal
structure (PDB id: 5E2B) using the program Gold53. The NTMT1 binding site was defined
by a sphere of 6.0 Å where the substrate MePPKRIA was extracted and the inhibitors
were docked into that site. The compounds for docking were prepared using SYBYL X2.1
and the energy was minimized using the external Tripos force field. The ChemPLP score
from the Gold53 docking program was considered to determine the most likely docking
conformations and top inhibitors.
The majority of the inhibitors overlaid well with the peptide substrate (MePPKRIA)
in the binding pocket of NTMT1. The docking studies verified that there is a large site at
the first position of the inhibitors which allowed for bulkier amino acid analogs at that
position. The docking studies also indicated that electrostatic interactions could occur if
an electronegative atom and hydrogen were introduced at the para position of the phenyl
ring at the first position. This supported our design to incorporate a hydroxy phenyl and
amino phenyl compound at the first position, which were substantiated by potent IC50
values. The peptide inhibitors, BM-30, BM-32, BM-34, BM-36 and BM-28 overlayed the
peptide substrate, MePPKRIA, are shown in Figure 12.
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Figure 12. Superimposed structures of peptide inhibitors (atom color) with substrate
peptide MePPKRIA (cyan) in the complex of NTMT1 (grey). (PDB: 5E2B) SAH is
shown in orange (A) BM-30; (B) BM-32; (C) BM-34; (D) BM-36; (E) BM-28.
2.1.3 Synthesis
The peptides were synthesized following the standard Fmoc solid-phase synthesis
on Rink amide resin using a CEM Liberty microwave peptide synthesizer.

The

peptidomimetics that have carboxylic acids at the first position were prepared through the
standard amino acid coupling reaction except for BM-45 which has a trimethylated Lys at
its 4th position. First, alloc protected Lys was manually coupled on to the Rink amide resin
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following the standard Fmoc strategy. Next, orthogonal deprotection of the alloc group
was performed using 3eq of I2 in 4:1 ACCN:H2O and shaken for 48 hours.201 followed by
trimethylation on the Lys side chain amine202 with an 80% yield after HPLC purification.
Then the remaining amino acids were coupled following standard coupling procedure
through the automatic peptide synthesizer (Scheme A1). For BM-26 and BM-27, the two
peptidomemetics with a benzyl group at the first position, benzyl bromide was used as
the starting material and added to the PKR and PKT tripeptide on resin through an SN2
reaction (Scheme A2). All compounds were cleaved from the solid support in a solution
of

trifluoroacetic

acid/2,2’-(ethylenedioxy)diethanethiol/H2O/triisopropylsilane

(94:2.5:2.5:1). All peptide inhibitors were purified by reverse-phase HPLC (Waters) and
characterized my mass spectrometry (Figure A1).
2.1.4 MALDI-MS Studies
To determine if the peptide inhibitors were possible substrates, the inhibitors
underwent a methylation progression study monitored via MALDI-MS as described
before.203 NTMT1 was incubated with the peptide inhibitors, and after 5 min, SAM was
added to initiate methylation. The reaction was quenched after one hour and the
compounds were analyzed through MALDI-MS and processed in Data Explorer. The
peptide inhibitors BM-11, BM-30, BM-32, BM-34, BM-39, and BM-42 were subjected to
NTMT1 methylation and none showed any methylation, indicating that they are not
NTMT1 substrates.
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To validate our inhibition values obtained from our fluorescence-based
methyltransferase assay, a MALDI-MS methylation progression assay was performed
following a similar procedure as described above. NTMT1 was incubated with RCC1-6
and the peptide inhibitors BM-11, BM-30, BM-34, BM-46 and BM-47 at two concentrations
(1 µM and 25 µM). After 5 min, SAM was added to initiate methylation of RCC1-6. The
reaction was quenched after one hour.203 The methylation progression was monitored via
MALDI-MS and data was analyzed in Data Explorer by quantifying the area under the
curve to determine the percentage of inhibition.203 The peptide inhibitors tested showed
similar inhibition values in this MALDI-MS methylation inhibition assay compared to the
fluorescence-based methyltransferase assay.

Figure 13 shows the MALDI-MS

methylation progression after the addition of the two concentrations of BM-30. The
inhibition values found in this assay are the same or comparable to the inhibition values

Figure 13. MALDI-MS methylation inhibition assay for peptide inhibitor BM-30
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found in the fluorescence assay. The four other peptide inhibitors tested are shown in
Figure A2-A5.
2.1.5 Inhibition Studies
All synthesized peptidomimetics were evaluated in our established SAH-coupled
fluorescence assay.192 The Km values for both peptide substrate and SAM were
determined as described before. The assay was performed at 100 µM of SAM and at the
Km value of peptide substrate. Initial screening was carried out at the concentration of 5
µM and 30 µM of each compound. Those compounds that exhibited more than 50% of
inhibition at 30 µM were subjected to IC50 studies. Percentage of inhibition is calculated
by subtracting the slope of [SAH] production vs. time for each concentration of inhibitor
from the slope of [SAH] production vs time of the positive control with no inhibitor present.
IC50 studies were carried out by ranging the inhibitor concentration from 0.14 µM – 100
µM in a three-fold dilution. They were incubated with 0.1 µM NTMT1 and the reaction
was initiated with the peptide substrate, RCC1-6 at Km value. Fluorescence intensity was
monitored for 15 min and the rates were fit to the log[inhibitor] vs response model using
least squares nonlinear regression. A summary of the kinetic data for the peptide
inhibitors is shown in Table A1 and IC50 curves are shown in Figure A6.
Table 5 shows all modifications made at the first position followed immediately by
a P-K-R sequence. The X groups consisted of many Pro mimics including cyclopentane,
cyclopentane, cyclohexane, phenyl and a benzyl moiety. Smaller groups to mimic Gly
and Ser were also incorporated in the X position. Finally, a larger aromatic group, a
quinolone, was also added to probe steric hindrances at the X position. All of these
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Table 5. Peptide inhibitors with 0 CH2 groups between carbonyl and X position

inhibitors also contained 0 CH2 groups between the carbonyl and X position. Interestingly,
none of these inhibitors showed inhibition toward NTMT1 at 100 µM. To explore the
importance of the carbonyl at the first position, it was removed in compounds BM-26 and
BM-27, and neither inhibitor showed any inhibitory activity at 100 µM. This lack of
inhibition may be an indicator of the significance of the hydrogen bond with the carbonyl
in that position or may be due to the distance of the X group.
On the other hand, introducing methylene or ethylene between the carbonyl and X
position led to a significant increase in inhibition (Table 6). While BM-2 showed no
inhibition at 100 µM, the addition of one more CH2 group in BM-9 led to an IC50 value of
33 µM. This was also observed in BM-41 and BM-42 which increased in inhibition after
the addition of a methylene group. The increase in inhibition from an extra CH2 group
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Table 6. Peptide inhibitors with 1-2 CH2 groups between carbonyl and X position

may indicate the need for more flexibility or distance at the first position. Alternatively, an
ethylene group led to a decrease in inhibition compared to the methylene analogs. BM32 had a 4.5-fold loss in inhibition after the incorporation of two CH2 groups compared to
BM-30. Similarly, BM-36 had a 3-fold loss in inhibition compared to BM-34. Therefore,
these results suggest that the optimum inhibitor for the NTMT1 binding site should have
a methylene group. Inhibitors which contain no CH2 groups may not have the distance
or flexibility to attain high inhibitory activity while two CH2 groups may cause steric
hindrances.
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Table 7. Structure-Activity-Relationship of modifications at 2nd position

Additionally, a variety of substituents were incorporated at the para position on the
X position, including a hydroxy group, an amine, a fluoro group and a methoxy group.
The inhibitors which contained a hydrogen donor at this para position, had the greatest
inhibitory effects. An 80-fold decrease in inhibition was found in BM-40, which had a
methoxy group, compared to BM-30, which had a hydroxy group. This supports the
necessity of a hydrogen donor at this first position.
Only one modification was made at the second position of the peptide inhibitors
and is shown in Table 7. Adding an alpha-methyl-Pro at the second position forces the
P2 to exist in a cis configuration,199 whereas Pro more only exists in the trans
configuration in our co-crystal structures.24 This modification led to a complete loss of
Table 8. Structure-Activity-Relationship of modifications at 3rd position

44

inhibition for BM-43. These results substantiate previous findings that a Pro at the second
position prefers the trans configuration; however, the additional methyl group may also
be contributed to the loss in inhibiton.
Many inhibitors were synthesized that had the sequence X-P-K-R and X-P-R-R
given that Lys and Arg exist in the third position of NTMT1 substrates. All inhibitors that
ended in the P-R-R sequence showed less inhibitory activity in the double dose
screenings compared to the P-K-R sequence. None of the inhibitors with an Arg at the
third position were evaluated in an IC50 assay due to low initial screenings. Table 8
indicates the preference for Lys over Arg at the third position.
Table 9. Peptide inhibitors with modifications at 4th position
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NTMT1 substrates have Arg and Thr at the fourth position; therefore, inhibitors
were synthesized with both amino acids at this position and are shown in Table 9. Every
inhibitor that ended in an Arg residue had greater inhibitory activity compared to its Thr
anolog. The inhibitors ending in Arg had 4- to 25-fold greater inhibition compared to their
Thr counterparts. These results indicate the significance of the Arg residue at the fourth
position. Eliminating the fourth amino acid entirely and converting the inhibitor to a trimer
also significantly diminished inhibition, which is shown by BM-44 compared to BM-30.
Two modifications were also made at the fourth position in attempts to increase
permeability or stability. Adding trimethylated Lys at the fourth position (BM-45) was
performed to increase permeability by adding three additional methyl groups, yet a
significant loss in inhibitory activity occurred. Converting L-Arg to the non-natural amino
acid D-Arg (BM-46) was carried out to increase stability against peptidases; however,
resulted in a four-fold loss in inhibition. Although there was a decrease in inhibition due
to this modification, there may be an increase in stability that is worth the loss in inhibition.
Lastly, the hexamer peptide compounds showed greater inhibition than their tetramer
analogs. BM-11 had a 12-fold increase in inhibition compared to BM-9, while BM-47 has
a 3-fold increase compared to BM-30 (Table 10). These results suggest that increasing
peptide inhibitor length increases inhibitory activity due to additional binding interactions.

Table 10. Tetramer and hexamer peptide analogs

46

2.3.6 Selectivity Studies
Given that there are many methyltransferase enzymes, selectivity among these
inhibitors is critical. For example, G9a is a methyltransferase that transfers a methyl to
Lys side chains while PRMT1 is a methyltransferase that transfers methyl groups to Arg
side chains. Both enzymes also share the conserved SAM binding site with NTMT1.
Therefore, selectivity of these compounds for NTMT1 is vital. The top five inhibitors with
IC50 values lower than 5 µM were tested against G9a and PRMT1 to ensure selectivity.
All peptide inhibitors except BM-46 showed >70 µM IC50 values against G9a and all the
inhibitors showed greater than >100 µM IC50’s against PRMT1. The results indicate that
Table 11. Summary of selectivity data for top peptide inhibitors
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the inhibitors have 3- to 300-fold selectivity for NTMT1 over these other two
methyltransferases. The selectivity data is summarized in Table 11.
2.3.7 Inhibition Mechanism
An inhibition mechanism study of one of the top inhibitors, BM-30, was performed
to verify which binding site the peptide inhibitor competes. Figure 14 shows the inhibitor
is acting through competitive inhibition with respect to the peptide substrate. This is
demonstrated by the linear dependence of the IC50 value relative to the increase in
peptide substrate concentration. Alternatively, BM-30 was noncompetitive with respect
to SAM, indicated by the flat line that minimally fluctuates based on SAM concentration.

Figure 14. BM-30 is a SAM-noncompetitive, peptide-competitive inhibitor of NTMT1.
BM-30 is competitive with the RCC1-6 peptide substrate, as the IC50 increases
linearly with with compound concentration. BM-30 does not compete with cofactor
SAM, as the IC50 was not affected by the compound.
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2.2 Photoaffinity Probes
2.2.1 Design
The goal is to identify the reader for α-N-terminal methylation to provide insight into
the NTMT1-regulated downstream pathway. Until now, there is no known interacting
partner that has been identified to recognize α-N-terminal methylation, except the NTMT
enzymes that install this methylation. Photoaffinity labeling has been used as an attractive
approach to identify binding partners, delineate drug-protein binding interactions, and
isolate cellular targets.204–207 Hence, we sought to apply a photoaffinity approach to catch
novel readers for α-N-terminal methylation. A typical photoaffinity probe contains three
main components: a recognition element, a crosslinker, and a clickable handle (Figure
15). The recognition element conveys selectivity, the photocrosslinker covalently tethers
the probe to the targets, and the clickable handle allows for derivations to link a
fluorescent reporter or biotinylated tag.

We initiated our efforts by optimizing our photoaffinity probes using NTMT1 which
is the only known interacting partner as the model system. Probes 1-3 contain an
unmethylated N-terminus and have the capability of being enzymatically recognized by
the NTMTs. Probes 4-6 have a methylated N-terminus and mimic the product of the
NTMT family and can be recognized by NTMT downstream reader proteins. Additionally,
NTMT still recognizes its methylated product; therefore, probes 4-6 can still be optimized
using NTMT1 as a model. To achieve specific photolabeling, we aim to position the
crosslinker close enough to the recognition motif while not interfering with the recognition.
Based on our co-crystal structures of NTMT1 in complex with substrates, the first four
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residues of the peptide substrate contribute significantly to the binding while the fifth and
sixth residues only form backbone hydrogen bonds with NTMT1 and are solventexposed.24 Hence, we decided to only incorporate the first four residues from selected
protein substrates as the specific recognition element and attached the crosslinker at
either the fifth or sixth position on our designed probes 1-6 (Figure 15). Among all tested
peptide substrates, substrate peptides starting with P-P-K have the highest binding affinity
for NTMT1 (1.5 nM) and can be efficiently methylated to the fully methylated state by
recombinant NTMT1.24, 191,203 Such substrate proteins include tumor suppressor RB1,
mouse RCC1, ribosomal subunits S25 and L12, and histone H2B; therefore, we initiated
our efforts by incorporating a P-P-K-T peptide that is derived from RB1 protein into probes
1, 2, 4, and 5 as the recognition element. In addition, we incorporated A-P-K-R that is
derived from oncoprotein SET as an alternative recognition element for probe 3 and 6

Figure 15. Structure of photoaffinity probes 1-6
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since validated substrates like oncoprotein SET, DDB2, and PARP3 contain the
sequence APK at their N-termini.

We initially selected a benzophenone as our crosslinker considering its
commercial availability, high stability and its preferential reaction with unreactive
C-H bonds.208 However, the benzophenone bulky size may also cause low labeling
efficiency and lead to nonspecific labeling. Therefore, we also synthesized photoMet to investigate the effect of a diazirine crosslinker,209 which is smaller in size.
The diazirine has high labeling efficiency and consequently increases the
sensitivity of the probe, although the reactive diazirine intermediate could also lead
to nonspecific labeling.210–212 Both crosslinkers were placed at either the fifth or
sixth amino acid position of the probe, which is after the recognition portion. Again,
this design was to minimize interference with the affinity of the recognition element
while still positioned in close enough proximity that it would specifically bind to the
target. One Gly linker was introduced right after the crosslinker (Probe 1) or one
on either side of the crosslinker (Probes 2-6) to allow conformational flexibility and
possibly prevent possible steric hindrance from interactions. 213 A propargyl group
was used as a clickable handle and added to the C-terminal of the peptide through
a Backbone Amide Linker (BAL) or propargylglycine.
2.2.2 Docking Studies

To support our design and further validate that the crosslinkers did not affect
binding within the active site, docking studies of the probes was performed using the
NTMT1 co-crystal structure (PDB id: 5E2B). The NTMT1 binding site was defined by a
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sphere of 6.0 Å where the substrate MePPKRIA was extracted and probes 1-3 were
docked into that site. The compounds for docking were prepared using SYBYL X2.1 and
the energy was minimized using the external Tripos force field. The ChemPLP score from
the Gold53 docking program was considered to determine the most likely docking
conformations and top inhibitors.

Probe 1 overlaid well with the peptide substrate

(MePPKRIA) in the binding pocket of NTMT1. The benzophenone crosslinker and the
alkyne portion pointed away from the surface of the protein. Probe 2 bound in a similar
A

B

C

Figure 16. Superimposed structures of probe 1-3 (yellow) with substrate peptide
MePPKRIA (cyan) in the complex of NTMT1 (grey). (PDB: 5E2B) SAH is shown in
orange (A) Probe 1; (B) Probe 2; (C) Probe 3.
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manner as probe 1 and the diazirine crosslinker still pointed to the surface of the protein.
Surprisingly, probe 3 displayed slightly different binding mode from the MePPKRIA
peptide, with the N-terminus in closer proximity to SAH. Nevertheless, the crosslinker
moieties of all three probes imposed minimal interference on binding to NTMT1 (Figure
16).

2.2.3 Synthesis
All probes were synthesized on solid phase via standard Fmoc peptide
coupling procedure. Briefly, the synthesis of photoaffinity Probe 1 is illustrated in
Scheme 1. The commercially available BAL handle was loaded onto Rink amide
resin first to yield 7.214 Compound 7 was converted to the alkyne, 8, after reductive
amination with propargylamine and sodium cyanoborohydride. 214 Next, a Gly linker
was manually coupled to yield 9 followed immediately with a manual coupling of
Fmoc-4-benzoyl-L-phenylalanine to yield 10. The N-terminal amino acids of PPKT

Scheme 1. Synthesis of photoaffinity probe 1 a) piperidine, HOBt, DMF, rink amide
resin, 2x10 min; HOBt, HBTU, DIPEA, NMP, 12 hr; Ac 2O, DCM, 2x5 min; b)
propargylamine, NaBH3CN, AcOH, MeOH, 2x12 hr; c) Fmoc-Gly-OH, DIC, NMP,
DCM, 2x90 min; Ac2O, DCM, 2x5 min; d) piperidine, HOBt, DMF, 2x10 min; Fmoc-4Bpa-L-phenylalanine, HOBt, DIC, DMF, 12 hr; e) automated iterative synthesis, µW,
Gly, Thr, Lys, Pro, Pro; f) trifluoroacetic acid, 2,2’-(ethylenedioxy)diethanethiol,
Triisopropylsilane, H2O, 4 hr.
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were added via a CEM Liberty microwave automatic peptide synthesizer to
produce 11 and followed by cleavage from resin to yield probe 1. Cleavage from
resin using trifluoroacetic acid (TFA) also cleaves the BAL linker from the probe.
The probe was verified by mass spectrometry with a detected mass of 787.5989
(predicted mass 787.4137). The synthesis of photoaffinity probe 4 is very similar
as the synthesis of probe 1, except the BAL linker is not cleaved after the addition
of TFA. Additionally, probe 4 was dimethylated using methyl iodide and potassium
carbonate.201 Probe 4 was cleaved and was verified by mass spectrometry with a
detected mass of 1035.5136 (predicted mass 1035.5304).
The syntheses of probes 2, 3, 5, and 6 were completed in a similar fashion except
Fmoc-propargylglycine was purchased from ChemImpex and manually coupled onto the
Rink amide resin. This step eliminated the incorporation of the Bal linker and the reductive
amination reaction. After successful coupling of the Fmoc-propargylglycine, manual
coupling of Fmoc-glycine and Fmoc-benzophenone or Fmoc-Photo-Met followed as
described above. The Fmoc-Photo-Met was synthesized as described in Yang, et al.209
The remaining amino acids were coupled using the automatic peptide synthesizer.
Probes 5 and 6 were then dimethylated or trimethylated and were also verified by mass
spectrometry with a detected mass of 817.4768 (predicted mass 817.4685) and 860.6093
(predicted mass 860.5219), respectively. Probes 2 and 3 were also verified by mass
spectrometry with a detected mass of 789.4373 (predicted mass 789.4366) and 930.4953
(predicted mass 930.4945), respectively. All six photoaffinity probes were purified by
reverse-phase HPLC (Waters) and characterized by mass spectrometry (Figure A7-A8).
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2.2.4 Recognition Studies

To validate the specific recognition of the probes, we first examined if our
unmethylated probes could be recognized and methylated by NTMT1 through a MSbased study. Briefly, photoaffinity probe 1 (5 µM) was incubated with NTMT1 (0.2 µM)
and SAM (50 µM) as reported previously.192,203 The reaction was monitored at various
time points via MALDI-MS. As shown in Figure 17, the photoaffinity probe was fully
methylated within five minutes in the presence of SAM as only dimethylated peak
([M+2Me]+ = 815.9542) was detected. This phenomenon indicates minimal interference
of the benzophenone with NTMT1 recognition and catalysis. This experiment was also
repeated with probe 3; however, after 15 min, there was a mixture of un-, mono-, and
dimethylated product (Figure A9).

Figure 17. MALDI-MS of probe 1 (theory m/z: 787.4143, detected m/z: 787.5989)
(left). MALDI-MS confirming photoaffinity probe 1 is fully dimethylated by NTMT1 in
the presence of S-adenosyl methionine (SAM) after 5 minutes (theory m/z: 815.4456,
detected m/z: 815.9542) (right).
In addition, we characterized the steady-state kinetic parameters of probes 1-3 for
methylation using an SAH hydrolase-coupled fluorescence assay, previously described
by Richardson, et al.192 The Km values of probes 1, 2 and 3 were found to be 4.9 ± 0.7
µM, 2.3 ± 0.1 µM and 0.7 ± 0.07 µM, respectively (Figure 18a-c, Table A2). To understand
55

b

a

d

c

e

Figure 18. Steady-state kinetics of His-NTMT1 activity as detected by fluorescence
assay. Varied concentration of (a) probe 1, (b) 2, (c) 3, (d) RB1-10, and (e) SET1-10
peptide with SAM at 100 µM.
how the crosslinker of the probes affects NTMT1 methylation, we also determined the Km
values of the RB1-10 (PPKTPRKTAA) and SET1-10 (APKRQSPLPP) peptides to be 0.9
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± 0.2 µM and 1.9 ± 0.2 µM, respectively (Figure 18d-e). Hence, the comparable Km values
of our probes and peptide substrates validate our design strategy.
2.2.5 Photoaffinity Labeling
To investigate the effect of probe concentration on labeling efficiency, NTMT1 (4
µM) was directly incubated with varying concentrations of the probes (0 µM to 16 µM) on
ice for 10 min and followed by irradiation for 30 min at 312 nm. 215 Tetramethylrhodamine
(TAMRA) azide and the “click” reagents were then added and incubated in the dark for
one hour. Then the samples were quenched with SDS loading dye and analyzed after
electrophoresis. In order to remove the excess fluorophore and eliminate background
noise from unreacted probes, the SDS-PAGE gels were washed with destaining buffer216
before the samples were quantified through fluorescence imaging analysis (Figure 19).

Figure 19. Concentration-dependence photolabeling of NTMT1 by (a) probe 1, (b)
probe 2, (c) probe 3, (d) probe 4, (e) probe 5 and (f) probe 6.
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The results showed that all six probes display a concentration-dependent manner
given that the amount of fluorescent labeling increases as the concentration of the probes
increases. The optimal concentration based on the signal-to-noise ratio and background
fluorescence was determined to be 8 µM for the probes which contain a benzophenone
(probes 1, 3 and 4) and 4 µM for probes which have a diazirine crosslinker (probes 2, 5
and 6). These concentrations of photoaffinity probes are used for all following studies.
A time-dependent study was performed to determine the optimal UV dosage for
efficient photocrosslinking. NTMT1 (4 µM) was incubated with benzophenone
photoaffinity probes 1, 2 and 4 (8 µM) on ice for 10 min then irradiated for 0, 10, 20, 30,
40 or 50 min at 312 nm.215 The diazirine crosslinker has been reported to have a much
faster crosslinking time; therefore, the time used for probes 2, 5 and 6 was 0, 2.5, 5, 7.5,
10 and 12.5 min or 0, 5, 10, 15 and 20 min.209 The results indicated that an optimal

Figure 20. Time-dependence photolabeling of NTMT1 by (a) probe 1, (b) probe 2, (c)
probe 3, (d) probe 4, (e) probe 5 and (f) probe 6.
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labeling was reached at approximately 30 min for the benzophenone probes 1, 3 and 4
(Figures 20a,c,d) and 10 min for the diazirine probes 2, 5 and 6 (Figure 20b,e,f).
To investigate if the labeling is specifically directed by recognition, we performed
NTMT1 labeling in the presence of an RB1-10 substrate peptide, which served as a
competitor to bind to NTMT1. NTMT1 (4 µM) was incubated with either competitor peptide
RB1-10 (0, 25, 50, 75 and 100 µM) or S-adenoyslhomocysteine (SAH) (0, 25, 50, 75 and
100 µM) on ice for 10 min to allow for any possible interaction. Next, photoaffinity probe
1 (8 µM) was added and incubated on ice for an additional 10 min to allow the probe to
compete with any of the possible interactions with NTMT1. Compared to the control, total
fluorescent labeling for probe 1 decreased over three-fold in the presence of 25 µM RB110, but did not significantly change in the presence of SAH (Figure 21). Since SAH binds
at the SAM binding site of NTMT1, our results validate that our designed photoaffinity
probes bind in the peptide binding pocket, revealing that the labeling is driven by specific
recognition.

Figure 21. Competition studies. (a) Cross-linking reactions of probe 1 with
recombinant NTMT1 in the presence of RB1-10 peptide at 0, 25, 50, 75, and 100 μM.
(b) Cross-linking reactions of probe 1 with recombinant NTMT1 in the presence of SAH
at 0, 25, 50, 75, and 100 μM.
Experiments were also carried out with RB1-10 and SAM at physiological
concentrations to evaluate if the photoaffinity probes still effectively label NTMT1.
Physiological concentrations of RB1 protein and SAM is reported to be 45 nM and 0.15
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µM, respectively. Therefore, NTMT1 (4 µM) was incubated with RB1-10 (0, 10, 25, 50,
75 and 100 nM) or cofactor SAM (0, 0.05, 0.1, 0.15, 0.2, and 0.25 µM) on ice for 10 min
to allow for any competition. Next, photoaffinity probe 2 (4 µM) was added and incubated
on ice for an additional 10 min to allow the probe to label NTMT1. Compared to the
control, total fluorescent labeling for probe 2 did not decrease in the presence of RB1 or
SAM (Figure 22). These results validate that these photoaffinity probes would be effective
in labeling NTMTs against physiological concentrations of competitors.

Figure 22. NTMT1 labeling with probe 2 at physiological concentrations of competitors
(a) Probe 2 with recombinant NTMT1 in the presence of RB1-10 peptide at 0, 10, 25,
50, 75, and 100 nM. (b) Probe 2 with recombinant NTMT1 in the presence of SAM at
0, 0.05, 0.1, 0.15, 0.2 and 0.25 μM.
Competition experiments were also performed with the probes 4-6 and a
methylated RB1-10 competitor. NTMT1 (4 µM) was incubated with either competitor
peptide Me2RB1-10 (0, 10, 20, 30, 40 or 100 µM) on ice for 10 min to allow for any possible
interaction. Next, the photoaffinity probes (8 or 4 µM) were added and incubated on ice
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for an additional 10 min to allow the probe to compete with any of the possible interactions
with NTMT1. Compared to the control, total fluorescent labeling for probe 4 decreased
over five-fold in the presence of 100 µM Me2RB1-10 (Figure 23a). Total percentage of
labeling of NTMT1 by photoaffinity probe 5 also decreased to 20% after introducing 10
µM of the Me2RB1-10 competitor (Figure 23b). Finally, total percentage of labeling by
probe 6 only decreased to 60% after introducing 10 µM of Me2RB1-10 (Figure 23c).
These results validate that our reader photoaffinity probes bind in the peptide binding
pocket, revealing that the labeling is driven by specific recognition.

Figure 23. Competition studies. (a) Cross-linking reactions of probe 4 with
recombinant NTMT1 in the presence of Me2RB1-10 peptide at 0 and 100 μM. (b)
Cross-linking reactions of probe 5 with recombinant NTMT1 in the presence of
Me2RB1-10 peptide at 0, 10, 2, 30 and 40 μM. (c) Cross-linking reactions of probe 6
with recombinant NTMT1 in the presence of Me2RB1-10 peptide at 0, 10, 2, 30 and 40
μM.
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Selectivity of the probes is critical for their applications in labeling specific
interactions. We assembled a pilot five-member panel of proteins including NTMT1,
bovine serum albumin (BSA), SAH hydrolase (SAHH), and two other protein
methyltransferases including euchromatic histone-Lys N-methyltransferase 2 (G9a) and
protein Arg methyltransferase 1 (PRMT1).

We performed the photoaffinity labeling

experiment for each member with our probes. Figure 24 show that probe 1 and probe 3
efficiently labeled NTMT1 more than 4- and 5-fold, respectively, over the other tested
proteins.

Figure 24. Selectivity studies. (a) Cross-linking reactions of probe 1 for a panel of five
recombinant enzymes. (b) Cross-linking reactions of probe 3 for a panel of five
recombinant enzymes.
Although the photoaffinity probes inferred selectivity among a panel of
methyltransferases, we wanted to ensure the photoaffinity probes were selective in a
complexed context like the cell lysate. Here, we incubated probes 1-3 (8 µM) with HeLa
cell lysates (1 mg/mL) that were spiked in with either NTMT1 or NTMT2 (4 µM) in the
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presence of a competitor peptide at various concentrations (0-50 µM). Within the whole
cell lysate, the photoaffinity probes specifically labeled NTMT1 and NTMT2 and did not
show labeling for any other proteins. For probe 1, the total fluorescent labeling for NTMT1
decreased to 4% and 2% in the presence of RB1-10 at 25 µM and 50 µM, respectively
(Figure 25a left). However, probe 1 labeling of NTMT2 only decreased to 66% and 34%
in the presence of 25 µM and 50 µM RB1-10, respectively (Figure 25a right). More
effective competition of RB1-10 peptide against probe 1 for NTMT1 over NTMT2 infers
that RB1-10 binds better to NTMT1 over NTMT2. The same substrate preference was
observed in the competition experiments with probe 2. Total labeling of NTMT1
decreased to 9% when incubated with 25 µM RB-10 and 4% when incubated with 50 µM
RB1-10 (Figure 25b left), while labeling of NTMT2 only decreased to 74% when incubated
with 25 µM RB-10 (Figure 25b right). Similar experiments were carried out with probe 3
with the addition of incorporating an APKRIA substrate competitor. After incubating 25
µM of RB1-10 or APKRIA, photoaffinity labeling of NTMT1 decreased to 25% and 60%,
respectively (Figure 25c left). Interestingly, labeling of NTMT2 decreased to 86% and
40%, respectively (Figure 25c right). These results imply that NTMT1 has a substrate
preference for PPKT over APKR which is substantiated by the kinetic analysis of these
two substrates shown in Figure 18 and Table A2. Furthermore, these results suggest that
NTMT2 prefers APKR substrate over PPKT.
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Figure 25. Photoaffinity labeling of probes 1-3 in HeLa cell lysates. (a) Probe 1
labeling in spiked cell lysates with NTMT1 (left) and NTMT2 (right) in presence of
competitor RB-10 peptide at 0, 25, and 50 μM. (b) Probe 2 labeling in spiked cell
lysates with NTMT1 (left) and NTMT2 (right) in presence of competitor RB-10 peptide
at 0, 25, and 50 μM (c) Probe 3 labeling in spiked cell lysates with NTMT1 (left) and
NTMT2 (right) without or with 25 μM RB-10 peptide or 25 μM APKRIA peptide.
64

3. Conclusions

The first series of peptide-based inhibitors have been synthesized that target
NTMT1. All 47 inhibitors were synthesized via solid-phase and an extensive structureactivity-relationship (SAR) has been developed.

The compounds with the greatest

inhibitory activity contain a hydrogen donor, like a hydroxy or amino group, at the first
amino acid in the para position. The optimum length between the first position and the
carbonyl of the second position Pro is one CH2 group. Pro at the P2 position is preferred
to alpha-methyl-Pro given its preference for the trans conformation. The inhibitors with a
Lys at the third position and an Arg at the fourth position are preferred for highest
inhibition. Among all synthesized tetrapeptidomimetics, our top inhibitor displays an IC 50
of 1.02 μM. Finally, extending the compound length from a tetramer to a hexamer, also
led to a 3- to 10-fold increase in inhibition. Thusly, seven inhibitors have IC50 values of
less than 5 µM and our top inhibitor has an IC50 value of 0.32 µM. Many of our top peptide
inhibitors were subjected to a MALDI-MS methylation inhibition assay and the results
substantiated the inhibitory values found from the fluorescent-based methyltransferase
assay. The inhibitor BM-30, also underwent an inhibition mechanism assay to validate
which NTMT1 binding site it is targeting. BM-30 was found to target the peptide substrate
binding site and not the SAM binding site. Lastly, the top five inhibitors underwent
selectivity studies with Lys methyltransferase, G9a, and Arg methyltransferase, PRMT1.
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All five inhibitors exhibited 3- to 300-fold selectivity for NTMT1 over the other
methyltransferases.
We have also designed, synthesized and characterized the first series of
photoaffinity probes that selectively label protein α-N-terminal methylation writers. A
critical issue in the design of photoaffinity probes is the positioning of the photoreactive
group and the selection of the recognition element, since it is imperative that the labeling
is regulated by specific recognition. Guided by our co-crystal structures and canonical XP-K motif, we have focused on incorporating an initial four amino acids; hence, we varied
two different recognition elements that were derived from protein substrate RB1 and SET.
Our photoaffinity probes have exhibited in a dose- and time-dependent manner to label
NTMT1/2. Additionally, labeling has proven to be driven by specific recognition given that
the photoaffinity probes can be enzymatically methylated by NTMT1 in a MS-based
methylation assay, and competitively inhibited in the presence of substrate peptide, RB110. Alternatively, probe labeling did not decrease in the presence of physiological
concentrations of RB1 or SAM, validating that the probes can be effective in a cellular
context. The designed probes also selectively label NTMT1 among a panel of enzymes
including other methyltransferase enzymes, G9a and PRMT1. Different labeling of
NTMT1 and NTMT2 by photoaffinity probes 1-3 in the presence of two substrate
competitors provides the first information to shed light on possible structural differences
or recognition preferences between NTMT1/2, which could aid in the design of selective
inhibitors for either NTMT family member. Furthermore, probes 1-3 have demonstrated
selectivity for NTMT1/2 in HeLa cell lysates, suggesting immense potential of utilizing
photoaffinity probes with a methylated α-N-terminus in the characterization of the protein
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α-N-terminal modification network. We anticipate using this strategy as a guide to design
the first probes to map the interacting protein partners of α-N-terminal methylation.
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4. Future Directions

Thus far, the peptidomimetic inhibitors have shown a lot of promise. The next step
is to determine stability and permeability of these inhibitors given that peptide-based
compounds are susceptible to peptidases and degradation in vivo. An LC-MS study can
be performed to verify stability of the compounds and a Caco-2 study can be carried out
to test permeability.

Based on the results of these studies, new inhibitors can be

synthesized with modifications to increase stability and permeability. Although eliminating
the amide bond between the first and second position resulted in no inhibitory activity,
elimination of the amide bond at the other positions should be attempted. Alternatively,
the amide bonds can also be methylated to increase stability. Incorporating more nonnatural amino acids like D-Arg, D-Lys, β-Arg, or β-Lys would also make these inhibitors
less prone to degradation. In order to increase permeability, lipophilic groups like can be
added to side chains of polar residues. Finally, the inhibitors need to be tested in cellbased and animal studies and inhibition of protein α-N-terminal methylation needs to be
evaluated at a cellular level.
The photoaffinity probes have been optimized for an NTMT1 model and have
demonstrated competitive labeling for NTMT1. Probes 1-3 have exhibited selective
labeling of spiked-in NTMT1 in a complex cell mixture. However, the next step is to
successfully pull-down NTMTs from a complex cell mixture without spiking-in the NTMTs.
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Identifying the NTMT writer proteins within the cell is critical to verify that the photolabeling
technique is effective at a cellular level. After successful optimization of pulling-down the
NTMT family using probes 1-3, the methylated photoaffinity probes (probes 4-6) can be
utilized to identify novel downstream proteins. Therefore, optimization of this approach
in a cellular context is critical.
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5. Methods

5.1 Materials and Reagents
All chemicals and reagents were used as purchased without further purification.
Most chemicals were purchased from Aldrich, Fisher, VWR, EMD, Calbiochem and
Chem-Impex.
5.2 Instruments
The peptide-based inhibitors and probes were synthesized on a CEM Liberty
microwave automatic peptide synthesizer. The compounds were purified by a C18
reverse-phase HPLC column (Waters).

The compounds were characterized by an

Applied Biosystems Voyager MALDI time-of-flight mass spectrometer in reflector mode
or by a Perkins Elmer ESI time-of-flight mass spectrometer in positive mode.
Visualization of the SDS-PAGE gel experiments was carried out by an Amersham gel
imager 600 at wavelength 520 and 630 nm.
5.3 Chemistry
5.3.1 Photoaffinity Probes
Probes 1-3 were prepared following the standard Fmoc strategy by solid-phase
synthesis on Rink amide resin. Fmoc removal was performed with 20% (v/v) piperidine in
DMF and 0.1M HOBt (2 x 10 min). After deprotection and coupling, the resin was washed
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with DMF (2x5 min), NMP (2x5 min), CH2Cl2 (2x5 min) and MeOH (2x5 min). Coupling of
a BAL linker (4 eq) was performed with HOBt (4 eq), HBTU (4 eq) and DIPEA (10 eq).214
Reductive amination was performed with propargylamine (20 eq) and sodium
cyanoborohydride (20 eq).214 For the probes without a BAL linker, coupling of Fmocpropagylglycine (2 eq) was performed with HOBt (2 eq) and DIC (2 eq). Coupling of
Fmoc-glycine (10 eq) was performed with DIC (5 eq) and HOBt (5 eq) and the coupling
of Fmoc-Bz or Fmoc-Dz209 (2 eq) was performed with HOBt (2 eq) and DIC (2 eq) in DMF.
Coupling of the sequence PPKT, APKRG or PPKTG was then performed using a CEM
Liberty microwave peptide synthesizer. The compounds were cleaved from the solid
support

in

a

solution

of

trifluoroacetic

acid/2,2’-

(ethylenedioxy)diethanethiol/H2O/triisopropylsilane (94:2.5:2.5:1) and confirmed by mass
spectrometry.
Probes 4-6 followed the same procedure as above. The methylation of the Nterminal amine occurred through the addition of iodomethane (5 eq) and K2CO3 (6 eq) in
DMF.202

The compounds were cleaved from the solid support in a solution of

trifluoroacetic acid/2,2’-(ethylenedioxy)diethanethiol/H2O/triisopropylsilane (94:2.5:2.5:1)
and confirmed by mass spectrometry.
5.3.2 Peptide Inhibitors
The peptides and peptide inhibitors were prepared following the standard Fmoc
strategy by solid-phase synthesis on Rink amide resin. All amino acid derivatives at the
first position were carboxylic acids to ensure that the standard amino acid coupling
reaction would still occur. Fmoc removal was performed with 20% (v/v) piperidine in DMF
and 0.1M HOBt (2 x 10 min). After deprotection and coupling, the resin was washed with
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DMF (2x5 min), NMP (2x5 min), CH2Cl2 (2x5 min) and MeOH (2x5 min). Synthesis of the
peptides and peptide inhibitors was performed using a CEM Liberty microwave peptide
synthesizer.
Three peptide inhibitors had a varying protocol from the one described above. The
first is inhibitor BM-45 had a trimethylated Lys residue at the fourth position. Alloc
protected Lys was coupled on to the Rink amide resin following the standard Fmoc
strategy. Next, orthogonal deprotection of the alloc group was performed using I2 (3 eq)
in 4:1 ACCN:H2O, shaken for 48 hours.201 Next, trimethylation of the Lys side chain amine
occurred through the addition of iodomethane (5 eq), K 2CO3 (6 eq), 18-crown-6 (0.1 eq)
in DMF.202 Then, standard coupling of the remaining amino acids occurred through the
automatic peptide synthesizer.
The other two peptide inhibitors synthesized with varying protocol from the
standard synthesizer were BM-26 and BM-27. Benzyl chloride (2 eq) and Cs2CO3 (2 eq)
in DMF were added to the PKR and PKT resin through an SN2 reaction. All compounds
were cleaved from the solid support in a solution of trifluoroacetic acid/2,2’(ethylenedioxy)diethanethiol/H2O/triisopropylsilane (94:2.5:2.5:1) and confirmed by mass
spectrometry.
5.4 Purification
5.4.1 Enzymes
His-NTMT1 was purified as previously described by Richardson, et al.192 The gene
of NTMT2 (58-278) was cloned into pET28-MKH8SUMO vector, NTMT2 was
overexpressed in Escherichia coli BL21 (DE3) cells by induction with 0.2mM IPTG at
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16°C overnight. The cells were harvested and purified by Ni-NTA, The SUMO tag was
removed by TEV protease, and the protein was further purified by ion-exchange column
and Superdex 200 gel filtration column. The gel filtration buffer contains 20mM Tris-HCl,
pH 7.5, 150mM NaCl and 1mM DTT. Enzymes G9a and PRMT1 were expressed in E.
Coli BL21 (DE3) codon plus RIL cells in LB medium in the presence of 50 µg/ml of
kanamycin, respectively.217,218
5.4.2 Chemical Probes and Inhibitors
All peptides, peptide inhibitors, and peptide-based photoaffinity probes were purified
by a C18 reverse-phase HPLC column (Waters). The compounds were characterized by
an Applied Biosystems Voyager MALDI time-of-flight mass spectrometer in reflector
mode or by a Perkins Elmer ESI time-of-flight mass spectrometer in positive mode. A
table of the predicted and detected masses can be found in Table A3.
5.5 MALDI-MS Methylation Studies
5.5.1 Methylation of Probe 1 and 3
NTMT1 (1 µL of 4 µM) was incubated with the photoaffinity probe (2 µL of 50 µM)
in Tris (2 µL of pH 7.5, 250 mM), KCl (2 µL of 500 mM) and 12 µL of H2O at 37°C. After
5 min, SAM (1 µL of 1 mM) was added to initiate methylation. The reaction was quenched
in a 1:1 ratio with quenching solution (50% MeCN:20 mM ammonium phosphate:0.4%
TFA) at 5, 10,

and 15 min.203 α-Cyano-3-hydroxycinnamic acid (CHCA) was

recrystallized and dissolved to a final concentration of 2 mg/mL in matrix solution (10mM
NH4H2PO4, 0.2% (v/v) TFA in 1:1 acetonitrile/water).
spotted with 1 µL of CHCA matrix solution.
73

Samples (1 µL) were directly

An average of five acquisitions were

performed for each well. The methylation progression was monitored via MALDI-MS and
data was processed in Data Explorer as described before. 203 Final concentrations are
NTMT1 (0.2 µM), probe (5 µM), Tris (pH 7.5, 25 mM), KCl (50 mM) and SAM (50 µM).
5.5.2 Methylation of Peptide Inhibitors
NTMT1 (1 µL of 4 µM) was incubated with the peptide inhibitors (2 µL of 50 µM) in
Tris (2 µL of pH 7.5, 250 mM), KCl (2 µL of 500 mM) and 12 µL of H2O at 37°C. After 5
min, SAM (1 µL of 1 mM) was added to initiate methylation. The reaction was quenched
with quenching solution (50% MeCN:20 mM ammonium phosphate:0.4% TFA) at 60
min.203 The methylation progression was monitored via MALDI-MS and data was
processed in Data Explorer as described before.203 Final concentrations are NTMT1 (0.2
µM), inhibitors (5 µM), Tris (pH 7.5, 25 mM), KCl (50 mM) and SAM (50 µM).
5.5.3 Methylation Progression of Substrate when Incubated with Inhibitors
NTMT1 (1 µL of 4 µM) was incubated with RCC1-6 (2 µL of 50 µM) in Tris (2 µL of
pH 7.5, 250 mM), KCl (2 µL of 500 mM) and 10 µL of H2O at 37°C. The peptide inhibitors
BM-11, BM-30, BM-34, BM-44, and BM-46 were then added at two concentrations (2 µL
of 10 µM or 250 µM). After 5 min, SAM (1 µL of 1 mM) was added to initiate methylation
of RCC1-6. The reaction was quenched with quenching solution (50% MeCN:20 mM
ammonium phosphate:0.4% TFA) at 60 min.203 The methylation progression was
monitored via MALDI-MS and data was analyzed in Data Explorer by quantifying the area
under the curve to determine the percentage of inhibition for each time point.203 Final
concentrations are NTMT1 (0.2 µM), RCC1-6 (5 µM), Tris (pH 7.5, 25 mM), KCl (50 mM),
SAM (50 µM) and inhibitors (1 µM and 25 µM).
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5.6 Docking Studies
All chemical probes and peptide inhibitors were docked into the NTMT1 co-crystal
structure (PDB id: 5E2B) using the program Gold53. The NTMT1 binding site was defined
by a sphere of 6.0 Å where the substrate MePPKRIA was extracted and the probes and
inhibitors were docked into that site. The compounds for docking were prepared using
SYBYL X2.1 and the energy was minimized using the external Tripos force field. The
ChemPLP score from the Gold53 docking program was considered to determine most
likely docking conformations and top inhibitors.
5.7 SDS-PAGE Gel Studies
5.7.1 Concentration-dependence
NTMT1 (2 µL of 1 mg/mL) was incubated in 96-well plates with the photoaffinity
probes at varying concentrations (2 µL of 0 µM, 10 µM, 20 µM, 40 µM, 80 µM, and 160
µM) in Tris (2 µL pH 7.5, 250 mM) and KCl (2 µL of 500 mM) and 12 μL of H2O on ice for
10 min for a total volume of 20 µL. The final concentrations are NTMT1 (0.1 mg/mL),
probes (0 µM, 1 µM, 2 µM, 4 µM, 8 µM, and 16 µM), Tris (pH 7.5, 25 mM) and KCl (50
mM). This solution was then irradiated for 10 min (for probes containing a diazirine
crosslinker) or 30 min (for probes containing a benzophenone crosslinker) at 312 nm and
4 °C. TAMRA azide (1 µL of 4.2 mM), aminoguanidine (9 µL of 12 µM), THPTA (4.5 µL
of 0.5 µM), CuSO4 (0.9 µL of 12 µM) and 35.6 µL of H2O were then premixed and 8.5 µL
of the mixed solution was aliquoted into individual Eppendorf tubes. The 96-well plate
solutions were then added to the premixed solution in the Eppendorf tubes, followed by
the addition of sodium ascorbate (1.5 µL of 100 µM) for a total volume of 30 µL and
reacted for one hour in the dark. The final concentrations are TAMRA azide (200 µM),
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aminoguanidine (5 µM), THPTA (0.1 µM), CuSO4 (0.5 µM) and sodium ascorbate (5 µM).
The reaction was quenched by the addition of 7.5 µL of 5x SDS loading dye. 20 µL of
each sample was loaded into an SDS-PAGE gel well and the reaction was analyzed on
SDS-PAGE gels (12%) at 180V for 50 min. The SDS-PAGE gels were washed with
destaining buffer (45% H2O:45% MeOH:10% AcOH) for one hour to remove excess
fluorescent reagents, followed by washing with water (3 x 1 min). Fluorescence was
detected with Amersham gel imager 600 at wavelength 520 and 630 nm. Next, the gel
was stained with Coomassie Blue R-250 for 1 hour, followed by destaining with 100%
destaining buffer for 1 hour and then 50:50 destaining buffer:H 2O overnight. The gels
were quantified using BioRad software by taking the ratio of the fluorescent band density
over the Coomassie band density to account for any inconsistencies in protein loading on
the gel. Studies were performed in duplicate.
5.7.2 Time-dependence
NTMT1 (2 µL of 1 mg/mL) was incubated in 96-well with the photoaffinity probes
(2 μL of 80 µM for probes with benzophenones, 2 μL of 40 μM for probes with diazirines)
in Tris (2 µL pH 7.5, 250 mM) and KCl (2 µL of 500 mM) and 12 μL of H2O on ice for 10
min for a total volume of 20 µL. The final concentrations are NTMT1 (0.1 mg/mL), probes
(8 or 4 µM), Tris (pH 7.5, 25 mM) and KCl (50 mM). Photoaffinity probes 1 and 3 were
then irradiated for 0 min, 10 min, 20 min, 30 min, 40 min or 50 min at a wavelength of 312
nm at 4 °C. Probe 2 was irradiated for 0 min, 2.5 min, 5 min, 7.5 min, 10 min or 12.5 min.
Probe 4 was irradiated for 0, 10, 20, 30 and 40 min while probes 5 and 6 were irradiated
for 0, 5, 10, 15, or 20 min. The click chemistry reaction and gel analysis was performed
as described above. Studies were performed in duplicate.
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5.7.3 Competition with Recombinant Protein
NTMT1 (2 µL of 1 mg/mL) was incubated in 96-well plates with the competitor RB110 (2 µL of 0, 250, 500, 750 or 1000 µM), RB1-10 (2 µL of 0, 100, 250, 500, 750, 1000
nM), Me2RB1-10 (2 µL of 0, 100, 200, 300 or 400 µM), SAH (2 µL of 0, 250, 500, 750 or
1000 µM) or SAM (2 µL of 0, 0.5, 1, 1.5, 2, 2.5 µM) in Tris (2 µL pH 7.5, 250 mM), KCl (2
µL 500 mM) and 8 µL of H2O for a total volume of 18 µL on ice for 10 min. Next,
photoaffinity probes with benzophenone crosslinkers (2 µL of 80 µM) or diazirine
crosslinkers (2 µL of 40 µM) were added for a final volume of 20 µL. The final
concentrations are NTMT1 (0.1 mg/mL), photoaffinity probes with benzophenone
crosslinkers (8 µM) or diazirine crosslinkers (4 µM), RB1-10 (0, 25, 50, 75 or 100 µM),
RB1-10 (0, 10, 25, 50, 75, 100 nM), Me2RB1-10 (0, 10, 20, 30 or 40 µM), SAH (0, 25, 50,
75 or 100 µM), SAM (0, 0.05, 0.1, 0.15, 0.2, 0.25 µM), Tris (pH 7.5, 25 mM) and KCl (50
mM). The photoaffinity probes were then irradiated for 30 min (probes with benzophenone
crosslinkers) or 10 min (probes with diazirine crosslinkers) at 312 nm and 4 °C. The
following click reaction and gel analysis was performed as described previously in the
time- and concentration-dependent studies. Studies were performed in duplicate.
5.7.4 Selectivity with Recombinant Protein
Each enzyme (BSA, NTMT1, G9a, SAHH PRMT1; 2 μL of 1 mg/mL) was incubated
in 96-well plates with photoaffinity probes 1 and 3 (2 μL of 80 µM) in Tris (2 μL of pH 7.5,
250 mM) and KCl (2 μL of 500 mM) and 12 µL of H2O for a total volume of 20 μL on ice
for 10 min then irradiated for 30 min at 312 nm and 4 °C. Final concentrations are
enzymes (0.1 mg/mL), photoaffinity probes 1 and 3 (8 µM), Tris (pH 7.5, 25 mM) and KCl
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(50 mM). The click chemistry reaction and gel analysis was performed as described
above. Studies were performed in duplicate.
5.7.5 Cell Lysate Studies
NTMT1 or NTMT2 (2 µL of 1 mg/mL) was spiked in to HeLa cell lysates (2 µL of 10
mg/mL) and incubated in 96-well plates with RB1-10 (2 µL of 0, 250, 500 µM) or APKRIA
(2 µL of 0, 250 µM) in Tris (2 µL of pH 7.5, 250 mM) and KCl (2 µL of 50 mM) and µL of
H2O for a total of 18 µL on ice for 10 min. Photoaffinity probes 1 and 3 (2 µL of 80 µM)
were then added on ice for 10 min and irradiated for 30 min at 312 nm and 4 °C, while
photoaffinity probe 2 (2 µL of 40 µM) was added on ice for 10 min and irradiated for 10
min at 312 nm and 4 °C. Final concentrations are NTMT1/2 (0.1 mg/mL), HeLa cell lysate
(1 mg/mL), photoaffinity probes 1 and 3 (8 µM) or photoaffinity probe 2 (4 µM), RB1-10
(0, 25, 50 µM) or APKRIA (0, 25 µM) in Tris (pH 7.5, 25 mM) and KCl (50 mM). The
following click reaction and gel analysis was performed as described previously. Studies
were performed in duplicate.
5.8 Kinetic Analysis of Compounds
5.8.1 Photoaffinity Probes
Kinetic characterization of the probes were determined using an SAH hydrolasecoupled fluorescence assay, which assess the production of SAH.192 Probes 1 and 3 were
incubated with NTMT1 (0.5 µL of 20 µM), while probe 2 was incubated with NTMT1 (0.5
µL of 10 µM). The reagents of the well-solution were added in the following order; H2O,
buffer (10 µL of 250 mM Tris, pH 7.4 and 500 mM KCl), SAM (1 µL of 10 mM), SAH
hydrolase (5 µL of 10 mg/mL), NTMT1 and ThioGlo1 (1 µL of 1.5 mM). After 10 min of
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incubation at 37 °C, the reaction was initiated with varying concentrations of each
photoaffinity probe in a two-fold dilution series (10 μL of 0 μM – 32 μM) for a total volume
of 100 µL. The final concentrations are buffer (25 mM Tris, pH 7.4 and 50 mM KCl), SAM
(100 µM), SAH hydrolase (10 µM), NTMT1 (0.1 or 0.05 µM), probe (0 – 32 μM) and
Thioglo1 (15 µM). Fluorescence intensity was monitored using a ClarioStar microplate
reader (Ex = 370 nm, Em=500 nm) at 37 °C for 15 min. The rates were fit to the MichaelisMenten model using least squares nonlinear regression through GraphPad Prism 7
software. All experiments were performed in triplicate.
5.8.2 Peptide Inhibitors
Kinetic characterization of the peptide inhibitors were determined using a similar
protocol as described abobe.192 The inhibitors ranging in concentration (1 μL of 0.014 mM
– 10 mM) and following a three-fold dilution were incubated in the well-solution that was
added in the following order: H2O, buffer (10 µL of 250 mM Tris, pH 7.4 and 500 mM KCl),
SAM (1 µL of 10 mM), SAH hydrolase (5 µL of 10 mg/mL), NTMT1 (0.5 µL of 40 µM) and
ThioGlo1 (1 µL of 1.5 mM). After 10 min of incubation at 37 °C, the reaction was initiated
with 10 μL of 50 µM RCC1-6 for a total volume of 100 µL. The final concentrations are
buffer (25 mM Tris, pH 7.4 and 50 mM KCl), SAM (100 µM), SAH hydrolase (10 µM),
NTMT1 (0.2 µM), inhibitors (0 – 100 μM), RCC1-6 (5 µM) and Thioglo1 (15 µM).
Fluorescence intensity was monitored using a ClarioStar microplate reader (Ex = 370 nm,
Em=500 nm) at 37 °C for 15 min. The rates were fit to the log[inhibitor] vs response model
using least squares nonlinear regression through GraphPad Prism 7 software.
experiments were performed in triplicate.
5.8.3 Inhibition Mechanism
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All

Kinetic analysis of one of the top inhibitors, BM-30, was performed to verify the
inhibition mechanism using the fluorescent-based assay described above.192,219 Six
independent IC50 studies of BM-30 were performed in triplicate with varying
concentrations of substrate peptide, RCC1-6 and SAM at its Km value. The inhibitors
ranging in concentration (1 μL of 0.14 µM – 10 mM) and following a three-fold dilution
were incubated in the well-solution that was added in the following order: H2O, buffer (10
µL of 250 mM Tris, pH 7.4 and 500 mM KCl), SAM (1 µL of 10 µM), SAH hydrolase (5 µL
of 10 mg/mL), NTMT1 (0.5 µL of 40 µM) and ThioGlo1 (1 µL of 1.5 mM). After 10 min of
incubation at 37 °C, the reaction was initiated with each concentration of RCC1-6 (10 μL
of 5, 10, 15, 20, 40, 80 μM) for a total volume of 100 µL. The final concentrations are
buffer (25 mM Tris, pH 7.4 and 50 mM KCl), SAM (1 µM), SAH hydrolase (10 µM), NTMT1
(0.2 µM), inhibitors (0 – 100 μM), RCC1-6 (0.25Km, 0.5Km, 0.75Km, Km, 2Km, and 4Km,
0.5, 1, 1.5, 2, 4, 8 μM, respectively) and Thioglo1 (15 µM). Fluorescence intensity was
monitored using a ClarioStar microplate reader (Ex = 370 nm, Em=500 nm) at 37 °C for
15 min. The rates were fit to the log[inhibitor] vs response model using least squares
nonlinear regression through GraphPad Prism 7 software. The average IC50 value of
each independent triplicate study was then plotted against the concentration of the
[RCC1-6]/Km.
Next, the same experiment was repeated with six IC50 studies of BM-30 in triplicate
at varying concentrations of SAM and RCC1-6 at its Km value. The inhibitors ranging in
concentration (1 μL of 0.14 µM – 10 mM) and following a three-fold dilution were
incubated in the well-solution that was added in the following order: H2O, buffer (10 µL of
250 mM Tris, pH 7.4 and 500 mM KCl), SAM (1 µL of 31.25, 62.5, 125, 250, 500, and
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1000 µM), SAH hydrolase (5 µL of 10 mg/mL), NTMT1 (0.5 µL of 40 µM) and ThioGlo1
(1 µL of 1.5 mM). After 10 min of incubation at 37 °C, the reaction was initiated with each
concentration of RCC1-6 (10 μL of 20 µM) for a total volume of 100 µL. The final
concentrations are buffer (25 mM Tris, pH 7.4 and 50 mM KCl), SAM (0.3125Km, 0.625Km,
1.25Km, 2.5Km, 5Km, and 10Km, 0.3125, 0.625, 1.25, 2.5, 5, 10 μM, respectively), SAH
hydrolase (10 µM), NTMT1 (0.2 µM), inhibitors (0 – 100 μM), RCC1-6 (2 μM) and Thioglo1
(15 µM). Fluorescence intensity was monitored using a ClarioStar microplate reader (Ex
= 370 nm, Em=500 nm) at 37 °C for 15 min. The rates were fit to the log[inhibitor] vs
response model using least squares nonlinear regression through GraphPad Prism 7
software. The average IC50 value of each independent triplicate study were plotted
against the concentration of the [SAM]/Km.
5.9 Selectivity studies
5.9.1 G9a
To determine selectivity, kinetic analysis of the peptide inhibitors were also carried
out using the SAH hydrolase-coupled fluorescence assay against G9a. The inhibitors
ranging in concentration (1 µL of 0 µM – 10 mM) and following a three-fold dilution were
incubated with a reaction mixture containing H2O, PBS buffer (10 µL of 10x buffer), SAM
(1 µL of 10 mM), SAH hydrolase (5 µL of 10 mg/mL), G9a (1 µL of 2.5 µM) and ThioGlo1
(1 µL of 1.5 mM). After 10 min of incubation at 37 °C, the reaction was initiated with 10
μL of 200 µM of H3-15.217 The final concentrations are buffer (1x PBS), SAM (100 µM),
SAH hydrolase (10 µM), G9a (25 nM), inhibitors (0 – 100 μM), H3-15 (20 μM) and
Thioglo1 (15 µM). Fluorescence intensity was monitored using a ClarioStar microplate
reader (Ex = 370 nm, Em=500 nm) at 37 °C for 15 min. The rates were fit to the
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log[inhibitor] vs response model using least squares nonlinear regression through
GraphPad Prism 7 software. All experiments were performed in triplicate.
5.9.2 PRMT1
To determine selectivity, kinetic analysis of the peptide inhibitors were also carried
out using the SAH hydrolase-coupled fluorescence assay against PRMT1. The inhibitors
ranging in concentration (1 µL of 0 µM – 10 mM) and following a three-fold dilution were
incubated with a reaction mixture containing H2O, buffer (10 µL of 25 mM HEPES, 250
mM NaCl, 250 µM EDTA, 500 µM TCEP), SAM (1 µL of 10 mM), SAH hydrolase (5 µL of
10 mg/mL), PRMT1 (2 µL of 10 µM) and ThioGlo1 (1 µL of 1.5 mM). After 10 min of
incubation at 37 °C, the reaction was initiated with H4-12 (10 µL of 1 mM).218 The final
concentrations are buffer (2.5 mM HEPES, 25 mM NaCl, 25 µM EDTA, 50 µM TCEP),
SAM (100 µM), SAH hydrolase (10 µM), PRMT1 (0.2 µM), inhibitors (0 – 100 μM), H4-12
(100 μM) and Thioglo1 (15 µM). Fluorescence intensity was monitored using a ClarioStar
microplate reader (Ex = 370 nm, Em=500 nm) at 37 °C for 15 min. The rates were fit to
the log[inhibitor] vs. response model using least squares nonlinear regression through
GraphPad Prism 7 software. All experiments were performed in triplicate.

82

List of References
1.

Gillette, T. G.; Hill, J. A. Readers, writers, and erasers: Chromatin as the whiteboard
of heart disease. Circ. Res. 2015, 116, 1245–1253.

2.

Lai, Z. W.; Petrera, A.; Schilling, O. Protein amino-terminal modifications and
proteomic approaches for N-terminal profiling. Curr. Opin. Chem. Biol. 2015, 24,
71–79.

3.

Varland, S.; Osberg, C.; Arnesen, T. N-terminal modifications of cellular proteins:
The enzymes involved, their substrate specificities and biological effects.
Proteomics 2015, 15, 2385–2401.

4.

Aksnes, H.; Hole, K.; Arnesen, T. Molecular, Cellular, and Physiological
Significance of N-Terminal Acetylation; Elsevier Ltd, 2015; Vol. 316.

5.

Mader, D.; Liebeke, M.; Winstel, V.; Methling, K.; Leibig, M.; Götz, F.; Lalk, M.;
Peschel, A. Role of N-terminal protein formylation in central metabolic processes in
Staphylococcus aureus. BMC Microbiol. 2013, 13, 1–9.

6.

Foyn, H.; Van Damme, P.; Stove, S. I.; Glomnes, N.; Evjenth, R.; Gevaert, K.;
Arnesen, T. Protein N-Terminal acetyltransferases act as N-Terminal
propionyltransferases in vitro and in vivo. Mol. Cell. Proteomics 2012, 42–54.

7.

Tooley, C. E. S.; Petkowski, J. J.; Muratore-Schroeder, T. L.; Balsbaugh, J. L.;
Shabanowitz, J.; Sabat, M.; Minor, W.; Hunt, D. F.; Macara, I. G. NRMT is an alphaN-methyltransferase that methylates RCC1 and retinoblastoma protein. Nature
2010, 466, 1125–1128.

8.

Buglino, J. A.; Resh, M. D. Palmitoylation of Hedgehog Proteins, 1st ed.; Elsevier
Inc., 2012; Vol. 88.

9.

Martin, D. D.; Beauchamp, E.; Berthiaume, L. G. Post-translational myristoylation:
Fat matters in cellular life and death. Biochimie 2011, 93, 18–31.

10.

Ciechanover, A.; Ben-Saadon, R. N-terminal ubiquitination: More protein
substrates join in. Trends Cell Biol. 2004, 14, 103–106.

11.

Polevoda, B.; Norbeck, J.; Takakura, H.; Blomberg, A.; Sherman, F. Identification
and specificities of N-terminal acetyltransferases from Saccharomyces cerevisiae.
EMBO J. 1999, 18, 6155–6168.

12.

Arnesen, T.; Van Damme, P.; Polevoda, B.; Helsens, K.; Evjenth, R.; Colaert, N.;
Varhaug, J. E.; Vandekerckhove, J.; Lillehaug, J. R.; Sherman, F.; Gevaert, K.
Proteomics analyses reveal the evolutionary conservation and divergence of Nterminal acetyltransferases from yeast and humans. Proc. Natl. Acad. Sci. U. S. A.
2009, 106, 8157–8162.
83

13.

Van Damme, P.; Evjenth, R.; Foyn, H.; Demeyer, K.; De Bock, P.; Lillehaug, J. R.;
Vandekerckhove, J.; Arnesen, T.; Gevaert, K. Proteome-derived peptide libraries
allow detailed analysis of the substrate specificities of N(alpha)-acetyltransferases
and point to hNaa10p as the post-translational actin N(alpha)-acetyltransferase.
Mol. Cell. proteomics MCP 2011, 10, 1–12.

14.

Van Damme, P.; Lasa, M.; Polevoda, B.; Gazquez, C.; Elosegui-Artola, A.; Kim, D.
S.; De Juan-Pardo, E.; Demeyer, K.; Hole, K.; Larrea, E.; Timmerman, E.; Prieto,
J.; Arnesen, T.; Sherman, F.; Gevaert, K.; Aldabe, R. N-terminal acetylome
analyses and functional insights of the N-terminal acetyltransferase NatB. Proc.
Natl. Acad. Sci. 2012, 109, 12449–12454.

15.

Polevoda, B.; Sherman, F. N-terminal acetyltransferases and sequence
requirements for N-terminal acetylation of eukaryotic proteins. J. Mol. Biol. 2003,
325, 595–622.

16.

Starheim, K. K.; Gromyko, D.; Evjenth, R.; Ryningen, A.; Varhaug, J. E.; Lillehaug,
J. R.; Arnesen, T. Knockdown of Human N -Terminal Acetyltransferase Complex C
Leads to p53-Dependent Apoptosis and Aberrant Human Arl8b Localization. Mol.
Cell. Biol. 2009, 29, 3569–3581.

17.

Hole, K.; van Damme, P.; Dalva, M.; Aksnes, H.; Glomnes, N.; Varhaug, J. E.;
Lillehaug, J. R.; Gevaert, K.; Arnesen, T. The human N-Alpha-acetyltransferase 40
(hNaa40p/hNatD) is conserved from yeast and N-terminally acetylates histones
H2A and H4. PLoS One 2011, 6, 9–15.

18.

Song, O. K.; Wang, X.; Waterborg, J. H.; Sternglanz, R. An N-alphaacetyltransferase responsible for acetylation of the N-terminal residues of histones
H4 and H2A. J. Biol. Chem. 2003, 278, 38109–38112.

19.

Van Damme, P.; Hole, K.; Pimenta-Marques, A.; Helsens, K.; Vandekerckhove, J.;
Martinho, R. G.; Gevaert, K.; Arnesen, T. NatF contributes to an evolutionary shift
in protein N-terminal acetylation and is important for normal chromosome
segregation. PLoS Genet. 2011, 7, 7–16.

20.

Towler, D. A.; Eubanks, S. R.; Towery, D. S.; Adams, S. P.; Glaser, L. Aminoterminal processing of proteins by N-myristoylation: Substrate specificity of Nmyristoyl transferase. J. Biol. Chem. 1987, 262, 1030–1036.

21.

Kozak, M. Comparison of initiation of protein synthesis in procaryotes, eucaryotes,
and organelles. Microbiol. Rev. 1983, 47, 1–45.

22.

Petkowski, J. J.; Bonsignore, L. A.; Tooley, J. G.; Wilkey, D. W.; Merchant, M. L.;
Macara, I. G.; Schaner Tooley, C. E. NRMT2 is an N-terminal monomethylase that
primes for its homologue NRMT1. Biochem. J. 2013, 456, 453–462.

23.

Wu, R.; Yue, Y.; Zheng, X.; Li, H. Molecular basis for histone N-terminal methylation
by NRMT1. Genes Dev. 2015, 29, 2337–2342.

24.

Dong, C.; Mao, Y.; Tempel, W.; Qin, S.; Li, L.; Loppnau, P.; Huang, R.; Min, J.
Structural basis for substrate recognition by the human N-terminal
84

methyltransferase 1. Genes Dev. 2015, 29, 2343–2349.
25.

Hamey, J. J.; Winter, D. L.; Yagoub, D.; Overall, C. M.; Hart-Smith, G.; Wilkins, M.
R. Novel N-terminal and Lys methyltransferases that target translation elongation
factor 1A in yeast and human. Mol. Cell. Proteomics 2016, 2, 164–176.

26.

Lee, K.-E.; Ahn, J.-Y.; Kim, J.-M.; Hwang, C.-S. Synthetic lethal screen of NAA20,
a catalytic subunit gene of NatB N-terminal acetylase in Saccharomyces cerevisiae.
J. Microbiol. 2014, 52, 842–848.

27.

Liszczak, G.; Goldberg, J. M.; Foyn, H.; Petersson, E. J.; Arnesen, T.; Marmorstein,
R. Molecular basis for N-terminal acetylation by the heterodimeric NatA complex.
Nat. Struct. Mol. Biol. 2013, 20, 1098–1105.

28.

Liszczak, G.; Arnesen, T.; Marmorsteins, R. Structure of a ternary Naa50p
(NAT5/SAN) N-terminal acetyltransferase complex reveals the molecular basis for
substrate-specific acetylation. J. Biol. Chem. 2011, 286, 37002–37010.

29.

Evjenth, R. H.; Brenner, A. K.; Thompson, P. R.; Arnesen, T.; Frøystein, N. Å.;
Lillehaug, J. R. Human protein N-terminal acetyltransferase hNaa50p
(hNAT5/hSAN) follows ordered sequential catalytic mechanism: Combined kinetic
and NMR study. J. Biol. Chem. 2012, 287, 10081–10088.

30.

Starheim, K. K.; Gevaert, K.; Arnesen, T. Protein N-terminal acetyltransferases:
when the start matters. Trends Biochem. Sci. 2012, 37, 152–161.

31.

Evjenth, R.; Hole, K.; Karlsen, O. A.; Ziegler, M.; Amesen, T.; Lillehaug, J. R.
Human Naa50p (Nat5/San) displays both protein Nα- and Nε-acetyltransferase
activity. J. Biol. Chem. 2009, 284, 31122–31129.

32.

Dyda, F.; Klein, D. C.; Hickman, A. B. GCN5-related N-acetyltransferases: A
structural overview. Annu Rev Biophys Biomol Struct 2000, 29, 81–103.

33.

Chang, Y.-Y.; Hsu, C.-H. Structural basis for substrate-specific acetylation of Nαacetyltransferase Ard1 from sulfolobus solfataricus. Sci. Rep. 2015, 5, 8673.

34.

Magin, R. S.; Liszczak, G. P.; Marmorstein, R. The molecular basis for Histone H4and H2A-specific amino-terminal acetylation by NatD. Structure 2015, 23, 332–341.

35.

Stove, S. I.; Magin, R. S.; Foyn, H.; Haug, B. E.; Marmorstein, R.; Arnesen, T.
Crystal structure of the golgi-associated human Na-acetyltransferase 60 reveals
the molecular determinants for substrate-specific acetylation. Structure 2016, 24,
1044–1056.

36.

Van Damme, P.; Lasa, M.; Polevoda, B.; Gazquez, C.; Elosegui-Artola, A.; Kim, D.
S.; De Juan-Pardo, E.; Demeyer, K.; Hole, K.; Larrea, E.; Timmerman, E.; Prieto,
J.; Arnesen, T.; Sherman, F.; Gevaert, K.; Aldabe, R. N-terminal acetylome
analyses and functional insights of the N-terminal acetyltransferase NatB. Proc.
Natl. Acad. Sci. 2012, 109, 12449–12454.

37.

Kalvik, T. V; Arnesen, T. Protein N-terminal acetyltransferases in cancer. Oncogene
2012, 32, 269–276.
85

38.

Hwang, C.-S.; Shemorry, A.; Varshavsky, A. N-terminal acetylation of cellular
proteins creates specific degradation signals. Science 2010, 327, 973–977.

39.

Hofmann, I. An N-terminally acetylated Arf-like GTPase is localised to lysosomes
and affects their motility. J. Cell Sci. 2006, 119, 1494–1503.

40.

Singer, J. M.; Shaw, J. M. Mdm20 protein functions with Nat3 protein to acetylate
Tpm1 protein and regulate tropomyosin-actin interactions in budding yeast. Proc.
Natl. Acad. Sci. U. S. A. 2003, 100, 7644–7649.

41.

Polevoda, B.; Sherman, F. Composition and function of the eukaryotic N-terminal
acetyltransferase subunits. Biochem. Biophys. Res. Commun. 2003, 308, 1–11.

42.

Bartels, T.; Kim, N. C.; Luth, E. S.; Selkoe, D. J. N-alpha-acetylation of α-synuclein
increases its helical folding propensity, GM1 binding specificity and resistance to
aggregation. PLoS One 2014, 9, 1–10.

43.

Forte, G. M.; Pool, M. R.; Stirling, C. J. N-Terminal Acetylation Inhibits Protein
Targeting to the Endoplasmic Reticulum. PLoS Biol. 2011, 9, e1001073.

44.

Rope, A. F.; Wang, K.; Evjenth, R.; Xing, J.; Johnston, J. J.; Swensen, J. J.;
Johnson, W. E.; Moore, B.; Huff, C. D.; Bird, L. M.; Carey, J. C.; Opitz, J. M.;
Stevens, C. A.; Jiang, T.; Schank, C.; Fain, H. D.; Robison, R.; Dalley, B.; Chin, S.;
South, S. T.; Pysher, T. J.; Jorde, L. B.; Hakonarson, H.; Lillehaug, J. R.; Biesecker,
L. G.; Yandell, M.; Arnesen, T. Using VAAST to identify an X-linked disorder
resulting in lethality in male infants due to N-terminal acetyltransferase deficiency.
Am. J. Hum. Genet. 2011, 89, 28–43.

45.

Arnesen, T.; Starheim, K. K.; Damme, P. Van; Evjenth, R.; Dinh, H.; Betts, M. J.;
Ryningen, A.; Gevaert, K.; Anderson, D. The chaperone-like protein HYPK acts
together with NatA in cotranslational N-terminal acetylation and prevention of
huntingtin aggregation. Mol. Cell. Biol. 2010, 30, 1898–1909.

46.

Asaumi, M.; Iijima, K.; Sumioka, A.; Iijima-Ando, K. Interaction of N-terminal
acetyltransferase with the cytoplasmic domain of β-amyloid precursor protein and
its effect on Aβ secretion. 2005, 137, 147–155.

47.

Fluge, Ø.; Bruland, O.; Akslen, L. A.; Varhaug, J. E.; Lillehaug, J. R. NATH, a novel
gene overexpressed in papillary thyroid carcinomas. Oncogene 2002, 21, 5056–
5068.

48.

Martin, D. T.; Gendron, R. L.; Jarzembowski, J. A.; Perry, A.; Collins, M. H.;
Pushpanathan, C.; Miskiewicz, E.; Castle, V. P.; Paradis, H. Tubedown expression
correlates with the differentiation status and aggressiveness of neuroblastic tumors.
Clin. Cancer Res. 2007, 13, 1480–1487.

49.

Linē, A.; Stengrēvics, A.; Slucka, Z.; Li, G.; Jankevics, E.; Rees, R. C. Serological
identification and expression analysis of gastric cancer-associated genes. Br. J.
Cancer 2002, 86, 1824–1830.

50.

Yu, M.; Gong, J.; Ma, M.; Yang, H.; Lai, J.; Wu, H.; Li, L.; Li, L.; Tan, D. Y.
Immunohistochemical analysis of human arrest-defective-1 expressed in cancers
86

in vivo. Oncol. Rep. 2009, 21, 909–915.
51.

Midorikawa, Y.; Tsutsumi, S.; Taniguchi, H.; Ishii, M.; Kobune, Y.; Kodama, T.;
Makuuchi, M.; Aburatani, H. Identification of genes associated with dedifferentiation
of hepatocellular carcinoma with expression profiling analysis. Jpn. J. Cancer Res.
2002, 93, 636–643.

52.

Lee, C. F.; Ou, D. S. C.; Lee, S. B.; Chang, L. H.; Lin, R. K.; Li, Y. S.; Upadhyay, A.
K.; Cheng, X.; Wang, Y. C.; Hsu, H. S.; Hsiao, M.; Wu, C. W.; Juan, L. J. HNaa10p
contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor
gene silencing. J. Clin. Invest. 2010, 120, 2920–2930.

53.

Ametzazurra, A.; Larrea, E.; Civeira, M. P.; Prieto, J.; Aldabe, R. Implication of
human N-α-acetyltransferase 5 in cellular proliferation and carcinogenesis.
Oncogene 2008, 27, 7296–7306.

54.

Foyn, H.; Jones, J. E.; Lewallen, D.; Narawane, R.; Varhaug, J. E.; Thompson, P.
R.; Arnesen, T. Design, synthesis, and kinetic characterization of protein N-terminal
acetyltransferase inhibitors. ACS Chem. Biol. 2013, 8, 1121–1127.

55.

Dormeyer, W.; Mohammed, S.; Van Breukelen, B.; Krijgsveld, J.; Heck, A. J. R.
Targeted analysis of protein termini. J. Proteome Res. 2007, 6, 4634–4645.

56.

Zhang, X.; Ye, J.; Højrup, P. A proteomics approach to study in vivo protein Nαmodifications. J. Proteomics 2009, 73, 240–251.

57.

Cai, L.; Sutter, B. M.; Li, B.; Tu, B. P. Acetyl-CoA induces cell growth and
proliferation by promoting the acetylation of histones at growth genes. Mol. Cell
2011, 42, 426–437.

58.

Hosokawa, Y.; Shimomura, Y.; Harris, R. A.; Ozawa, T. Determination of shortchain acyl-coenzyme A esters by high-performance liquid chromatography. Anal.
Biochem. 1986, 153, 45–49.

59.

Tooley, J. G.; Schaner Tooley, C. E. New roles for old modifications: Emerging roles
of N-terminal post-translational modifications in development and disease. Protein
Sci. 2014, 23, 1641–1649.

60.

Khandwala, A. S.; Kasper, C. B. The Fatty Acid Composition of Individual
Phospholipids from Rat Liver Nuclear Membrane and Nuclei. J. Biol. Chem. 1971,
246, 6242–6246.

61.

Sugii, M.; Okada, R.; Matsuno, H.; Miyano, S. Performance improvement in protein
N-Myristoyl classification by bonsai with insignificant indexing symbol. Genome
Informatics 2007, 18, 277–286.

62.

Maurer-Stroh, S.; Eisenhaber, B.; Eisenhaber, F. N-terminal N-Myristoylation of
Proteins: Prediction of Substrate Proteins from Amino Acid Sequence. J. Mol. Biol.
2002, 317, 541–557.

63.

Jennings, B. C.; Linder, M. E. Regulation of G proteins by covalent modification.
Handb. Cell Signaling, 2/e 2010, 2, 1629–1633.
87

64.

Boutin, J. A. Myristoylation. Cell. Signal. 1997, 9, 15–35.

65.

Muszbek, L.; Laposata, M. Myristoylation of proteins in platelets occurs
predominantly through thioester linkages. J. Biol. Chem. 1993, 268, 8251–8255.

66.

Robbins, S. M.; Quintrell, N. A.; Bishop, J. M. Myristoylation and differential
palmitoylation of the HCK protein-tyrosine kinases govern their attachment to
membranes and association with caveolae. Mol. Cell. Biol. 1995, 15, 3507–3515.

67.

Yonemoto, W.; McGlone, M. L.; Taylor, S. S. N-myristylation of the catalytic subunit
of cAMP-dependent protein kinase conveys structural stability. J. Biol. Chem. 1993,
268, 2348–2352.

68.

Raju, R. V; Moyana, T. N.; Sharma, R. K. N-Myristoyltransferase overexpression in
human colorectal adenocarcinomas. Exp. Cell Res. 1997, 235, 145–154.

69.

Cox, A. D.; Der, C. J. Protein prenylation: more than just glue? Curr. Opin. Cell Biol.
1992, 4, 1008–1016.

70.

Kataoka, M.; Mihars, K.; Tokunaga, F. Recoverin alters its surface properties
depending on both calcium-binding and N-terminal myristoylation. J.Biochem.
1993, 114, 535–540.

71.

Raju, R. V; Kakkar, R.; Datla, R. S.; Radhi, J.; Sharma, R. K. Myristoyl-coA:protein
N-myristoyltransferase from bovine cardiac muscle: molecular cloning, kinetic
analysis, and in vitro proteolytic cleavage by m-calpain. Exp. Cell Res. 1998, 241,
23–35.

72.

Giang, D. K.; Cravatt, B. F. A second mammalian N-myristoyltransferase. J. Biol.
Chem. 1998, 273, 6595–6598.

73.

Gelb, M. H.; Van Voorhis, W. C.; Buckner, F. S.; Yokoyama, K.; Eastman, R.;
Carpenter, E. P.; Panethymitaki, C.; Brown, K. A.; Smith, D. F. Protein farnesyl and
N-myristoyl transferases: Piggy-back medicinal chemistry targets for the
development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem.
Parasitol. 2003, 126, 155–163.

74.

Ducker, C. E. Two N-myristoyltransferase ssozymes play unique roles in protein
myristoylation, proliferation, and apoptosis. Mol. Cancer Res. 2005, 3, 463–476.

75.

Lu, Y.; Selvakumar, P.; Ali, K.; Shrivastav, A.; Bajaj, G.; Resch, L.; Griebel, R.;
Fourney, D.; Meguro, K.; Sharma, R. K. Expression of N-myristoyltransferase in
human brain tumors. Neurochem. Res. 2005, 30, 9–13.

76.

Selvakumar, P.; Lakshmikuttyamma, A.; Sharma, R. K. Biochemical
characterization of bovine brain myristoyl-CoA:protein N-myristoyltransferase type
2. J. Biomed. Biotechnol. 2009, 2009, 907614.

77.

Bhatnagar, R.; Fütterer, K.; Waksman, G.; Gordon, J. The structure of myristoylCoA:protein N-myristoyltransferase. Biochim. Biophys. Acta 1999, 1441, 162–167.

78.

Zhao, C.; Ma, S. Recent advances in the discovery of N-myristoyltransferase
88

inhibitors. ChemMedChem 2014, 9, 2425–2437.
79.

Rocque, W. J.; McWherter, C. A.; Wood, D. C.; Gordon, J. I. A comparative analysis
of the kinetic mechanism and peptide substrate specificity of human and
Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. J. Biol.
Chem. 1993, 268, 9964–9971.

80.

Rudnick, D. A.; Rocque, W. J.; McWherter, C. A.; Toth, M. V; Jackson-Machelski,
E.; Gordon, J. I. Use of photoactivatable peptide substrates of Saccharomyces
cerevisiae myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) to characterize a
myristoyl-CoA-Nmt1p-peptide ternary complex and to provide evidence for an
ordered reaction mechanism. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 1087–1091.

81.

Yamauchi, S.; Fusada, N.; Hayashi, H.; Utsumi, T.; Uozumi, N.; Endo, Y.; Tozawa,
Y. The consensus motif for N-myristoylation of plant proteins in a wheat germ cellfree translation system. FEBS J. 2010, 277, 3596–3607.

82.

Bhatnagar, R. S.; Gordon, J. I. Understanding covalent modifications of proteins by
lipids: Where cell biology and biophysics mingle. Trends Cell Biol. 1997, 7, 14–20.

83.

Chen, L.; Ling, B.; Alcorn, J.; Yang, J. Quantitative analysis of the expression of
human N-myristoyltransferase 1 (hNMT-1) in cancers. Open Biomark. J. 2009, 1,
6–10.

84.

Shrivastav, A.; Varma, S.; Saxena, A.; DeCoteau, J.; Sharma, R. K. Nmyristoyltransferase: a potential novel diagnostic marker for colon cancer. J. Transl.
Med. 2007, 5, 58–63.

85.

Rajala, R. V. S.; Radhi, J. M.; Kakkar, R.; Datla, R. S. S.; Sharma, R. K. Increased
expression of N-myristoyltransferase in gallbladder carcinomas. Cancer 2000, 88,
1992–1999.

86.

Shrivastav, A.; Suri, S. S.; Mohr, R.; Janardhan, K. S.; Sharma, R. K.; Singh, B.
Expression and activity of N-myristoyltransferase in lung inflammation of cattle and
its role in neutrophil apoptosis. Vet. Res. 2010, 41, 1–12.

87.

Georgopapadakou, N. H. Antifungals targeted to protein modification: focus on
protein N-myristoyltransferase. Expert Opin. Investig. Drugs 2002, 11, 1117–1125.

88.

Gunaratne, R. S.; Sajid, M.; Ling, I. T.; Tripathi, R.; Pachebat, J. A.; Holder, A. A.
Characterization of N-myristoyltransferase from Plasmodium falciparum. Biochem.
J. 2000, 348 Pt 2, 459–463.

89.

Price, H. P.; Menon, M. R.; Panethymitaki, C.; Goulding, D.; Mckean, P. G.; Smith,
D. F.; Leishmania, I. Myristoyl-CoA: Protein N-myristoyltransferase, an essential
enzyme and potential drug target in kinetoplastid parasites. J. Biol. Chem. 2003,
278, 7206–7214.

90.

Wright, M. H.; Clough, B.; Rackham, M. D.; Rangachari, K.; Brannigan, J. A.;
Grainger, M.; Moss, D. K.; Bottrill, A. R.; Heal, W. P.; Broncel, M.; Serwa, R. A.;
Brady, D.; Mann, D. J.; Leatherbarrow, R. J.; Tewari, R.; Wilkinson, A. J.; Holder,
A. A.; Tate, E. W. Validation of N-myristoyltransferase as an antimalarial drug target
89

using an integrated chemical biology approach. Nat. Chem. 2014, 6, 112–121.
91.

Kawasaki, K. ichi; Masubuchi, M.; Morikami, K.; Sogabe, S.; Aoyama, T.; Ebiike,
H.; Niizuma, S.; Hayase, M.; Fujii, T.; Sakata, K.; Shindoh, H.; Shiratori, Y.; Aoki,
Y.; Ohtsuka, T.; Shimma, N. Design and synthesis of novel benzofurans as a new
class of antifungal agents targeting fungal N-myristoyltransferase. Part 3.
Bioorganic Med. Chem. Lett. 2003, 13, 87–91.

92.

Taha, M. O.; Qandil, A. M.; Al-Haraznah, T.; Khalaf, R. A.; Zalloum, H.; Al-Bakri, A.
G. Discovery of new antifungal leads via pharmacophore modeling and QSAR
analysis of fungal N-myristoyl transferase inhibitors followed by In Silico screening.
Chem. Biol. Drug Des. 2011, 78, 391–407.

93.

Gilbert, I. H. Drug discovery for neglected diseases: Molecular target-based and
phenotypic approaches. J. Med. Chem. 2013, 56, 7719–7726.

94.

Tate, E. W.; Bell, A. S.; Rackham, M. D.; Wright, M. H. N-Myristoyltransferase as a
potential drug target in malaria and leishmaniasis. Parasitology 2014, 141, 37–49.

95.

Das, U.; Kumar, S.; Dimmock, J. R.; Sharma, R. K. Inhibition of protein Nmyristoylation: A therapeutic protocol in developing anticancer agents. Curr.
Cancer Drug Targets 2012, 12, 667–692.

96.

Linder, M. E.; Deschenes, R. J. Palmitoylation: policing protein stability and traffic.
Nat. Rev. Mol. Cell Biol. 2007, 8, 74–84.

97.

Aicart-Ramos, C.; Valero, R. A.; Rodriguez-Crespo, I. Protein palmitoylation and
subcellular trafficking. Biochim. Biophys. Acta 2011, 1808, 2981–2994.

98.

Pepinsky, R. B.; Zeng, C.; Rayhorn, P.; Baker, D. P.; Williams, P.; Bixler, S. A.;
Christine, M.; Garber, E. A.; Taylor, F. R.; Elizabeth, A.; Galdes, A.; Wen, D.;
Williams, K. P.; Ambrose, C. M.; Miatkowski, K.; Wang, E. a. Identification of a
palmitic acid-modified form of human sonic hedgehog. J. Biol. Chem. 1998, 273,
14037–14045.

99.

Fuccillo, M.; Joyner, A. L.; Fishell, G. Morphogen to mitogen: the multiple roles of
hedgehog signalling in vertebrate neural development. Nat. Rev. Neurosci. 2006,
7, 772–783.

100. Buglino, J. A.; Resh, M. D. Hhat is a palmitoylacyltransferase with specificity for Npalmitoylation of Sonic Hedgehog. J. Biol. Chem. 2008, 283, 22076–22088.
101. Chang, C. C. Y.; Sun, J.; Chang, T.-Y. Membrane-bound O-acyltransferases
(MBOATs). Front. Biol. (Beijing). 2011, 6, 177–182.
102. Hoffman, K. A superfamily of membrane-bound O-acetyltansferases with
implications for Wnt signalling. Trends Biochem. Sci. 2000, 25, 111–112.
103. Taylor, F. R.; Wen, D.; Garber, E. A.; Carmillo, A. N.; Baker, D. P.; Arduini, R. M.;
Williams, K. P.; Weinreb, P. H.; Rayhorn, P.; Hronowski, X.; Whitty, A.; Day, E. S.;
Boriack-Sjodin, A.; Shapiro, R. I.; Galdes, A.; Pepinsky, R. B. Enhanced potency of
human Sonic hedgehog by hydrophobic modification. Biochemistry 2001, 40,
90

4359–4371.
104. Chen, M. H.; Li, Y. J.; Kawakami, T.; Xu, S. M.; Chuang, P. T. Palmitoylation is
required for the production of a soluble multimeric Hedgehog protein complex and
long-range signaling in vertebrates. Genes Dev. 2004, 18, 641–659.
105. Constantinides, P. P.; Steim, J. M. Physical properties of fatty acyl-CoA. J. Biol.
Chem. 1985, 260, 7573–7580.
106. Hardy, R. Y.; Resh, M. D. Identification of N-terminal residues of sonic hedgehog
important for palmitoylation by Hedgehog acyltransferase. J. Biol. Chem. 2012,
287, 42881–42889.
107. Buglino, J. A.; Resh, M. D. Identification of conserved regions and residues within
hedgehog acyltransferase critical for palmitoylation of Sonic hedgehog. PLoS One
2010, 5, 17–20.
108. Yang, J.; Brown, M. S.; Liang, G.; Grishin, N. V.; Goldstein, J. L. Identification of
the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide
hormone. Cell 2008, 132, 387–396.
109. Bosson, R.; Jaquenoud, M.; Conzelmann, A. GUP1 of Saccharomyces cerevisiae
encodes an O-acyltransferase involved in remodeling of the GPI anchor. Mol. Biol.
Cell 2006, 17, 2636–2645.
110. Guo, Z. Y.; Lin, S.; Heinen, J. A.; Chang, C. C. Y.; Chang, T. Y. The active site His460 of human acyl-coenzyme A:cholesterol acyltransferase 1 resides in a hitherto
undisclosed transmembrane domain. J. Biol. Chem. 2005, 280, 37814–37826.
111. Konitsiotis, A. D.; Chang, S. C.; Jovanovic, B.; Ciepla, P.; Masumoto, N.; Palmer,
C. P.; Tate, E. W.; Couchman, J. R.; Magee, A. I. Attenuation of hedgehog
acyltransferase-catalyzed sonic hedgehog palmitoylation causes reduced
signaling, proliferation and invasiveness of human carcinoma cells. PLoS One
2014, 9, e89899.
112. Justilien, V.; Walsh, M. P.; Ali, S. A.; Thompson, E. A.; Murray, N. R.; Fields, A. P.
The PRKCI and SOX2 oncogenes are co-amplified and cooperate to activate
Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014, 25, 139–
151.
113. Matevossian, A.; Resh, M. D. Hedgehog Acyltransferase as a target in estrogen
receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells. Mol.
Cancer 2015, 14, 72.
114. Petrova, E.; Matevossian, A.; Resh, M. D. Hedgehog acyltransferase as a target in
pancreatic ductal adenocarcinoma. Oncogene 2015, 34, 263–268.
115. Petrova, E.; Rios-Esteves, J.; Ouerfelli, O.; Glickman, J. F.; Resh, M. D. Inhibitors
of Hedgehog acyltransferase block Sonic Hedgehog signaling. Nat. Chem. Biol.
2013, 9, 247–249.
116. Goldstein, G.; Scheid, M.; Hammerling, U.; Schlesinger, D. H.; Niall, H. D.; Boyse,
91

E. A. Isolation of a polypeptide that has lymphocyte-differentiating properties and is
probably represented universally in living cells. Proc. Natl. Acad. Sci. U. S. A. 1975,
72, 11–15.
117. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001,
70, 503–533.
118. Pickart, C. M.; Eddins, M. J. Ubiquitin: Structures, functions, mechanisms. Biochim.
Biophys. Acta 2004, 1695, 55–72.
119. McDowell, G. S.; Philpott, A. Non-canonical ubiquitylation: Mechanisms and
consequences. Int. J. Biochem. Cell Biol. 2013, 45, 1833–1842.
120. Breitschopf, K.; Bengal, E.; Ziv, T.; Admon, A.; Ciechanover, A. A novel site for
ubiquitination: The N-terminal residue, and not internal Lyss of MyoD, is essential
for conjugation and degradation of the protein. EMBO J. 1998, 17, 5964–5973.
121. Bloom, J.; Amador, V.; Bartolini, F.; DeMartino, G.; Pagano, M. Proteasomemediated degradation of p21 via N-terminal ubiquitinylation. Cell 2003, 115, 71–82.
122. Scaglione, K. M.; Basrur, V.; Ashraf, N. S.; Konen, J. R.; Elenitoba-Johnson, K. S.
J.; Todi, S. V.; Paulson, H. L. The ubiquitin-conjugating enzyme (E2) ube2w
ubiquitinates the N terminus of substrates. J. Biol. Chem. 2013, 288, 18784–18788.
123. Sadeh, R.; Breitschopf, K.; Bercovich, B.; Zoabi, M.; Kravtsova-Ivantsiv, Y.;
Kornitzer, D.; Schwartz, A.; Ciechanover, A. The N-terminal domain of MyoD is
necessary and sufficient for its nuclear localization-dependent degradation by the
ubiquitin system. Proc. Natl. Acad. Sci. 2008, 105, 15690–15695.
124. Coulombe, P.; Rodier, G.; Bonneil, E.; Thibault, P. N-terminal ubiquitination of
extracellular signal-regulated Kinase 3 and p21 directs their degradation by the
proteasome. Mol. Cell. Biol. 2004, 24, 6140–6150.
125. Kuo, M. L.; Den Besten, W.; Bertwistle, D.; Roussel, M. F.; Sherr, C. J. N-terminal
polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 2004,
18, 1862–1874.
126. Ben-Saadon, R.; Fajerman, I.; Ziv, T.; Hellman, U.; Schwartz, A. L.; Ciechanover,
A. The tumor suppressor protein p16INK4a and the human papillomavirus
oncoprotein-58 E7 are naturally occurring Lys-less proteins that are degraded by
the ubiquitin system: Direct evidence for ubiquitination at the N-terminal residue. J.
Biol. Chem. 2004, 279, 41414–41421.
127. Reinstein, E.; Scheffner, M.; Oren, M.; Ciechanover, A.; Schwartz, A. Degradation
of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system:
targeting via ubiquitination of the N-terminal residue. Oncogene 2000, 19, 5944–
5950.
128. Aviel, S.; Winberg, G.; Massucci, M.; Ciechanover, A. Degradation of the EpsteinBarr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway:
Targeting via ubiquitination of the N-terminal residue. J. Biol. Chem. 2000, 275,
23491–23499.
92

129. Ikeda, M.; Ikeda, A.; Longnecker, R. Lys-independent ubiquitination of Epstein–
Barr virus LMP2A. Virology 2002, 300, 153–159.
130. Li, H.; Okamoto, K.; Peart, M. J.; Prives, C. Lys-independent turnover of cyclin G1
can be stabilized by B’alpha subunits of protein phosphatase 2A. Mol. Cell. Biol.
2009, 29, 919–928.
131. Wang, Y.; Shao, Q.; Yu, X.; Kong, W.; Hildreth, J. E. K.; Liu, B. N-terminal
hemagglutinin tag renders Lys-deficient APOBEC3G resistant to HIV-1 Vif-induced
degradation by reduced polyubiquitination. J. Virol. 2011, 85, 4510–4519.
132. Traasch-Azar, J. S.; Lingbeck, J.; Ciechanover, A.; Schwartz, A. L. Ubiquitinproteasome-mediated degradation of Id1 is modulated by MyoD. J. Biol. Chem.
2004, 279, 32614–32619.
133. Trausch-Azar, J.; Leone, T. C.; Kelly, D. P.; Schwartz, A. L. Ubiquitin proteasomedependent degradation of the transcriptional coactivator PGC-1a via the N-terminal
pathway. J. Biol. Chem. 2010, 285, 40192–40200.
134. Vosper, J. M. D.; McDowell, G. S.; Hindley, C. J.; Fiore-Heriche, C. S.; Kucerova,
R.; Horan, I.; Philpott, A. Ubiquitylation on canonical and non-canonical sites targets
the transciption factor neurogenin for ubiquitin-mediated proteolysis. J. Biol. Chem.
2009, 284, 15458–15468.
135. Tatham, M. H.; Plechanovová, A.; Jaffray, E. G.; Salmen, H.; Hay, R. T. Ube2W
conjugates ubiquitin to α-amino groups of protein N-termini. Biochem. J. 2013, 453,
137–145.
136. Yang, J.; Hong, Y.; Wang, W.; Wu, W.; Chi, Y.; Zong, H.; Kong, X.; Wei, Y.; Yun,
X.; Cheng, C.; Chen, K.; Gu, J. HSP70 protects BCL2L12 and BCL2L12A from Nterminal ubiquitination-mediated proteasomal degradation. FEBS Lett. 2009, 583,
1409–1414.
137. Fajerman, I.; Schwartz, A. L.; Ciechanover, A. Degradation of the Id2
developmental regulator: Targeting via N-terminal ubiquitination. Biochem.
Biophys. Res. Commun. 2004, 314, 505–512.
138. McDowell, G. S.; Kucerova, R.; Philpott, A. Non-canonical ubiquitylation of the
proneural protein Ngn2 occurs in both Xenopus embryos and mammalian cells.
Biochem. Biophys. Res. Commun. 2010, 400, 655–660.
139. Vittal, V.; Shi, L.; Wenzel, D. M.; Scaglione, K. M.; Duncan, E. D.; Basrur, V.;
Elenitoba-Johnson, K. S. J.; Baker, D.; Paulson, H. L.; Brzovic, P. S.; Klevit, R. E.
Intrinsic disorder drives N-terminal ubiquitination by Ube2w. Nat Chem Biol 2015,
11, 83–89.
140. Mukhopadhyay, D.; Riezman, H. Proteasome-independent functions of ubiquitin in
endocytosis and signaling. Science (80-. ). 2007, 315, 201–205.
141. Schnell, J. D.; Hicke, L. Non-traditional functions of ubiquitin and ubiquitin-binding
proteins. J. Biol. Chem. 2003, 278, 35857–35860.
93

142. Garcia-Higuera, I.; Taniguchi, T.; Ganesan, S.; Meyn, M. S.; Timmers, C.; Hejna,
J.; Grompe, M.; D’Andrea, A. D. Interaction of the Fanconi anemia proteins and
BRCA1 in a common pathway. Mol. Cell 2001, 7, 249–262.
143. Hochstrasser, M. Evolution and function of ubiquitin-like protein-conjugation
systems. Nat. Cell Biol. 2000, 2, E153-157.
144. Varshavsky, A. The ubiquitin system. Annu. Rev. Biochem. 1998, 22, 383–387.
145. Hershko, A.; Ciechanover, A.; Rose, I. A. Identification of the active amino acid
residue of the polypeptide of ATP-dependent protein breakdown. J. Biol. Chem.
1981, 256, 1525–1528.
146. Wu, P. Y.; Hanlon, M.; Eddins, M.; Tsui, C.; Rogers, R. S.; Jensen, J. P.; Matunis,
M. J.; Weissman, A. M.; Wolberger, C. P.; Pickart, C. M. A conserved catalytic
residue in the ubiquitin-conjugating enzyme family. EMBO J. 2003, 22, 5241–5250.
147. Hershko, A.; Heller, H.; Elias, S.; Ciechanover, A. Components of ubiquitin-protein
ligase system. J. Biol. Chem. 1983, 258, 8206–8214.
148. Koegl, M.; Hoppe, T.; Schlenker, S.; Ulrich, H. D.; Mayer, T. U.; Jentsch, S. A novel
ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999, 96,
635–644.
149. Grossman, S. R.; Deato, M. E.; Brignone, C.; Chan, H. M. Polyubiquitination of p53
by a ubiquitin ligase activity of p300. Science (80-. ). 2003, 300, 342–344.
150. Thrower, J. S.; Hoffman, L.; Rechsteiner, M.; Pickart, C. M.; Amerik, A.;
Swaminathan, S.; Krantz, B.; Wilkinson, K.; Hochstrasser, M.; Pickart, C.; et al.
Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000, 19, 94–102.
151. Komander, D.; Rape, M. The ubiquitin code. Annu. Rev. Biochem. 2012, 81, 203–
229.
152. Lecker, S. H. Protein degradation by the ubiquitin-proteasome pathway in normal
and disease states. J. Am. Soc. Nephrol. 2006, 17, 1807–1819.
153. Bedford, L.; Lowe, J.; Dick, L. R.; Mayer, R. J.; Brownell, J. E. Ubiquitin-like protein
conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug
Discov. 2011, 10, 29–46.
154. Kessler, B. M. Ubiquitin - omics reveals novel networks and associations with
human disease. Curr. Opin. Chem. Biol. 2013, 17, 59–65.
155. Corti, O.; Lesage, S.; Brice, A. What genetics tells us about the causes and
mechanisms of Parkinson’s disease. Physiol Rev. 2011, 91, 1161–1218.
156. Adhikary, S.; Marinoni, F.; Hock, A.; Hulleman, E.; Popov, N.; Beier, R.; Bernard,
S.; Quarto, M.; Capra, M.; Goettig, S.; Kogel, U.; Scheffner, M.; Helin, K.; Eilers, M.
The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is
essential for tumor cell proliferation. Cell 2005, 123, 409–421.
157. Li, M.; Brooks, C. L.; Wu-baer, F.; Chen, D.; Baer, R.; Li, M.; Brooks, C. L.; Wu94

baer, F.; Chen, D. Mono- versus polyubiquitination: Differential control of p53 fate
by Mdm2. Science (80-. ). 2003, 302, 1972–1975.
158. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.;
Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R.
Z.; Kuter, D.; Limentani, S. a; Lee, S.; Hideshima, T.; Esseltine, D.-L.; Kauffman,
M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in
relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609–2617.
159. Cohen, P.; Tcherpakov, M. Will the ubiquitin system furnish as many drug targets
as protein kinases? Cell 2010, 143, 686–693.
160. Rentsch, A.; Landsberg, D.; Brodmann, T.; B??low, L.; Girbig, A. K.; Kalesse, M.
Synthesis and pharmacology of proteasome inhibitors. Angew. Chemie - Int. Ed.
2013, 52, 5450–5488.
161. Zhang, W.; Sidhu, S. S. Development of inhibitors in the ubiquitination cascade.
FEBS Lett. 2014, 588, 356–367.
162. Adams, J. M.; Capecchi, M. N-Formylmethionyl-sRNA as the initiator of protein
synthesis. Proc. Natl. Acad. Sci. 1966, 55, 147–155.
163. Marcker, K.; Sanger, F. N-Formyl-methionyl-S-RNA. J. Mol. Biol. 1964, 8, 835–IN8.
164. Newton, D. T.; Creuzenet, C.; Mangroo, D. Formylation is not essential for initiation
of protein synthesis in all eubacteria. J. Biol. Chem. 1999, 274, 22143–22146.
165. Margolis, P. S.; Hackbarth, C. J.; Young, D. C.; Wang, W.; Chen, D.; Yuan, Z.;
White, R.; Trias, J. Peptide deformylase in Staphylococcus aureus: Resistance to
inhibition is mediated by mutations in the formyltransferase gene. Antimicrob.
Agents Chemother. 2000, 44, 1825–1831.
166. Mader, D.; Liebeke, M.; Winstel, V.; Methling, K.; Leibig, M.; Götz, F.; Lalk, M.;
Peschel, A. Role of N-terminal protein formylation in central metabolic processes in
Staphylococcus aureus. BMC Microbiol. 2013, 13, 1–9.
167. Galkin, A.; Kulakova, L.; Sarikaya, E.; Lim, K.; Howard, A.; Herzberg, O. Structural
insight into Arg degradation by Arg deiminase, an antibacterial and parasite drug
target. J. Biol. Chem. 2004, 279, 14001–14008.
168. Leeds, J. A.; Dean, C. R. Peptide deformylase as an antibacterial target: a critical
assessment. Curr. Opin. Pharmacol. 2006, 6, 445–452.
169. Mazel, D.; Pochet, S.; Marliere, P. Genetic characterization of polypeptide
deformylase, a distinctive enzyme of eubacterial translation. EMBO J. 1994, 13,
914–923.
170. Giglione, C.; Pierre, M.; Meinnel, T. Peptide deformylase as a target for new
generation, broad spectrum antimicrobial agents. Mol. Microbiol. 2000, 36, 1197–
1205.
171. Chen, D. Z.; Patel, D. V.; Hackbarth, C. J.; Wang, W.; Dreyer, G.; Young, D. C.;
95

Margolis, P. S.; Wu, C.; Ni, Z. J.; Trias, J.; White, R. J.; Yuan, Z. Actinonin, a
naturally occurring antibacterial agent, is a potent deformylase inhibitor.
Biochemistry 2000, 39, 1256–1262.
172. Jain, R.; Chen, D.; White, R. J.; Patel, D. V; Yuan, Z. Bacterial Peptide deformylase
inhibitors: a new class of antibacterial agents. Curr. Med. Chem. 2005, 12, 1607–
1621.
173. Clements, J. M.; Beckett, R. P.; Brown, A.; Catlin, G.; Lobell, M.; Palan, S.; Thomas,
W.; Whittaker, M.; Wood, S.; Salama, S.; Baker, P. J.; Rodgers, H. F.; Barynin, V.;
Rice, D. W.; Hunter, M. G. Antibiotic activity and characterization of BB-3497, a
novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 2001, 45, 563–
570.
174. Molteni, V.; He, X.; Nabakka, J.; Yang, K.; Kreusch, A.; Gordon, P.; Bursulaya, B.;
Warner, I.; Shin, T.; Biorac, T.; Ryder, N. S.; Goldberg, R.; Doughty, J.; He, Y.
Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorganic
Med. Chem. Lett. 2004, 14, 1477–1481.
175. Verma, S. K.; Jat, R. K.; Nagar; N, L.; Saharan, R.; Sharma, V.; Pandey, S.; Bansal,
K. A novel antibacterial target: Peptidyl deformylase. Pharmacophore 2011, 2, 114–
123.
176. Azoulay-Dupuis, E.; Mohler, J.; Bédos, J. P. Efficacy of BB-83698, a novel peptide
deformylase inhibitor, in a mouse model of Pneumococcal Pneumonia. Antimicrob.
Agents Chemother. 2004, 48, 80–85.
177. Naderer, O. J.; Jones, L. S.; Zhu, J.; Kurtinecz, M.; Dumont, E. Safety, tolerability,
and pharmacokinetics of oral and intravenous administration of GSK1322322, a
peptide deformylase inhibitor. J. Clin. Pharmacol. 2013, 53, 1168–1176.
178. Wittmann-Liebold, B.; Pannenbecker, R. Primary structure of protein L33 from the
large subunit of the Escherichia Coli ribosome. FEBS Lett. 1976, 68, 115–118.
179. Martinage, A.; Briand, G.; Van Dorsselaer, A.; Turner, C. H.; Sautiere, P. Primary
structure of histone H2B from gonads of the starfish Asterias rubens. Eur. J.
Biochem. 1985, 147, 351–359.
180. Pettigrew, G. W.; Smith, G. M. Novel N-terminal protein blocking group identified
as dimethylproline. Nature 1977, 265, 661–662.
181. Henry, G. D.; Winstanley, M. A.; Dalgarno, D. C.; Scott, G. M. M.; Levine, B. A.;
Trayer, I. P. Characterization of the actin-binding site on the alkali light chain of
myosin. Biochim. Biophys. Acta 1985, 830, 223–243.
182. Webb, K. J.; Lipson, R. S.; Al-hadid, Q.; Whitelegge, J. P.; Clarke, S. G.
Identification of protein N-terminal methyltransferases in yeast and humans.
Biochemistry 2010, 49, 5225–5235.
183. Bonsignore, L. A.; Tooley, J. G.; Van Hoose, P. M.; Wang, E.; Cheng, A.; Cole, M.
P.; Schaner Tooley, C. E. NRMT1 knockout mice exhibit phenotypes associated
with impaired DNA repair and premature aging. Mech. Ageing Dev. 2015, 146–148,
96

42–52.
184. Cai, Q.; Fu, L.; Wang, Z.; Gan, N.; Dai, X.; Wang, Y. A-N-methylation of damaged
DNA-binding protein 2 (DDB2) and its function in nucleotide excision repair. J. Biol.
Chem. 2014, 289, 16046–16056.
185. Dai, X.; Otake, K.; You, C.; Cai, Q.; Wang, Z.; Masumoto, H.; Wang, Y. Identification
of novel α-N-methylation of CENP-B that regulates its binding to the centromeric
DNA. J. Proteome Res. 2013, 12, 4167–4175.
186. Bailey, A. O.; Panchenko, T.; Sathyan, K. M.; Petkowski, J. J.; Pai, P.-J.; Bai, D. L.;
Russell, D. H.; Macara, I. G.; Shabanowitz, J.; Hunt, D. F.; Black, B. E.; Foltz, D. R.
Posttranslational modification of CENP-A influences the conformation of
centromeric chromatin. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 11827–11832.
187. Chen, T.; Muratore, T. L.; Schaner-Tooley, C. E.; Shabanowitz, J.; Hunt, D. F.;
Macara, I. G. N-terminal alpha-methylation of RCC1 is necessary for stable
chromatin association and normal mitosis. Nat. Cell Biol. 2007, 9, 596–603.
188. Stock, A.; Clarke, S.; Stock, J. N-terminal methylation of proteins: structure, function
and specificity. FEBS Lett. 1987, 220, 8–14.
189. Villar-Garea, A.; Forne, I.; Vetter, I.; Kremmer, E.; Thomae, A.; Imhof, A.
Developmental regulation of N-terminal H2B methylation in Drosophila
melanogaster. Nucleic Acids Res. 2012, 40, 1536–1549.
190. Antonysamy, S.; Bonday, Z.; Campbell, R. M.; Doyle, B.; Druzina, Z.; Gheyi, T.
Crystal structure of the human PRMT5:MEP50 complex. Proc. Natl. Acad. Sci.
2012, 109, 1–6.
191. Petkowski, J. J.; Tooley, C. E. S.; Anderson, L. C.; Shumilin, I. A.; Balsbaugh, J. L.;
Hunt, D. F.; Minor, W.; Macara, I. G. Substrate specificity of mammalian N-terminal
α-amino methyltransferase NRMT. Biochemistry 2012, 51, 5942–5950.
192. Richardson, S. L.; Mao, Y.; Zhang, G.; Hanjra, P.; Peterson, D. L.; Huang, R. Kinetic
mechanism of protein N-terminal methyltransferase 1. J. Biol. Chem. 2015, 290,
11601–11610.
193. Bonsignore, L. A.; Butler, J. S.; Klinge, C. M.; Tooley, C. E. S.; Schaner Tooley, C.
E. Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA
damage and promotes mammary oncogenesis. Oncotarget 2015, 6, 12248–12263.
194. Uhlen, M.; Bjo, E.; Agaton, C.; Szigyarto, C. A.; Amini, B.; Andersen, E.; Andersson,
A.; Angelidou, P.; Asplund, A.; Ponte, F.; et al. A human protein atlas for normal
and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 2005, 4,
1920–1932.
195. Dowden, J.; Hong, W.; Parry, R. V; Pike, R. A.; Ward, S. G. Toward the
development of potent and selective bisubstrate inhibitors of protein Arg
methyltransferases. Bioorg. Med. Chem. Lett. 2010, 20, 2103–2105.
196. Osborne, T.; Roska, R. L. W.; Rajski, S. R.; Thompson, P. R. In situ generation of
97

a bisubstrate analogue for protein Arg methyltransferase 1. J. Am. Chem. Soc.
2008, 130, 4574–4575.
197. Zhang, G.; Richardson, S. L.; Mao, Y.; Huang, R. Design, synthesis, and kinetic
analysis of potent protein N-terminal methyltransferase 1 inhibitors. Org. Biomol.
Chem. 2015, 13, 4149–4154.
198. Zhang, G.; Huang, R. Facile synthesis of SAM–peptide conjugates through alkyl
linkers targeting protein N-terminal methyltransferase 1. RSC Adv. 2016, 6, 6768–
6771.
199. De Poli, M.; Moretto, A.; Crisma, M.; Peggion, C.; Formaggio, F.; Kaptein, B.;
Broxterman, Q. B.; Toniolo, C. Is the backbone conformation of Cα-methyl proline
restricted to a single region? Chem. - A Eur. J. 2009, 15, 8015–8025.
200. Stuckey, J. I.; Simpson, C.; Norris-Drouin, J. L.; Cholensky, S. H.; Lee, J.; Pasca,
R.; Cheng, N.; Dickson, B. M.; Pearce, K. H.; Frye, S. V.; James, L. I. Structureactivity relationships and kinetic studies of peptidic antagonists of CBX
chromodomains. J. Med. Chem. 2016, 59, 8913–8923.
201. Szumigala, R. H.; Onofiok, E.; Karady, S.; Armstrong, J. D.; Miller, R. A. Mild nontransition metal catalyzed deprotection of N-allyloxycarbonyl amines. Tetrahedron
Lett. 2005, 46, 4403–4405.
202. Santhiya, D.; Dias, R. S.; Shome, A.; Das, P. K.; Miguel, M. G.; Lindman, B.; Maiti,
S. Role of linker groups between hydrophilic and hydrophobic moieties of cationic
surfactants on oligonucleotide-surfactant interactions. Langmuir 2009, 25, 13770–
13775.
203. Richardson, S. L.; Hanjra, P.; Zhang, G.; Mackie, B. D.; Peterson, D. L.; Huang, R.
A direct, ratiometric, and quantitative MALDI–MS assay for protein
methyltransferases and acetyltransferases. Anal. Biochem. 2015, 478, 59–64.
204. Schmidinger, H.; Hermetter, A.; Birner-Gruenberger, R. Activity-based proteomics:
Enzymatic activity profiling in complex proteomes. Amino Acids 2006, 30, 333–350.
205. Willems, L. I.; Overkleeft, H. S.; Van Kasteren, S. I. Current developments in
activity-based protein profiling. Bioconjug. Chem. 2014, 25, 1181–1191.
206. Cravatt, B. F.; Wright, A. T.; Kozarich, J. W. Activity-based protein profiling: from
enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 2008, 77, 383–
414.
207. Serim, S.; Haedke, U.; Verhelst, S. H. L. Activity-based probes for the study of
proteases: Recent advances and developments. ChemMedChem 2012, 7, 1146–
1159.
208. Dormán, G.; Prestwich, G. D. Benzophenone photophores in biochemistry.
Biochemistry 1994, 33, 5661–5673.
209. Yang, T.; Liu, Z.; Li, X. D. Developing diazirine-based chemical probes to identify
histone modification “readers” and “erasers.” Chem. Sci. 2015, 6, 1011–1017.
98

210. Dubinsky, L.; Krom, B. P.; Meijler, M. M. Diazirine based photoaffinity labeling.
Bioorganic Med. Chem. 2012, 20, 554–570.
211. Hancock, S. M.; Uprety, R.; Deiters, A.; Chin, J. W. Expanding the genetic code of
yeast for incorporation of diverse unnatural amino acids via a pyrrolysyl-tRNA
synthetase/tRNA pair. J. Am. Chem. Soc. 2010, 132, 14819–14824.
212. Meng Zhang, P. C. A genetically incorporated crosslinker reveals chaperone
cooperation in acid resistance. Nat. Chem. Biol. 2011, 7, 671–677.
213. Kawamura, A.; Hindi, S.; Mihai, D. M.; James, L.; Aminova, O. Binding is not
enough: Flexibility is needed for photocrosslinking of Lck kinase by benzophenone
photoligands. Bioorganic Med. Chem. 2008, 16, 8824–8829.
214. Brandt, M.; Gammeltoft, S.; Jensen, K. J. Microwave heating for solid-phase
peptide synthesis: General evaluation and application to 15-mer phosphopeptides.
Int. J. Pept. Res. Ther. 2006, 12, 349–357.
215. Morozov, Y. I.; Agaronyan, K.; Cheung, A. C. M.; Anikin, M.; Cramer, P.; Temiakov,
D. A novel intermediate in transcription initiation by human mitochondrial RNA
polymerase. Nucleic Acids Res. 2014, 42, 3884–3893.
216. Montgomery, D. C.; Sorum, A. W.; Meier, J. L. Chemoproteomic profiling of Lys
acetyltransferases highlights an expanded landscape of catalytic acetylation. J.
Am. Chem. Soc. 2014, 136, 8669–8676.
217. Liu, F.; Chen, X.; Allali-hassani, A.; Quinn, A. M.; Wigle, T. J.; Wasney, G. A.; Dong,
A.; Senisterra, G.; Chau, I.; Siarheyeva, A.; Norris, J. L.; Kireev, D. B.; Jadhav, A.;
Herold, J. M.; Janzen, W. P.; Arrowsmith, C. H.; Frye, S. V; Brown, P. J.; Simeonov,
A. Protein Lys methyltransferase G9a inhibitors: Design, synthesis, and structure
activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J. Med. Chem.
2010, 373, 5844–5857.
218. Feng, Y.; Xie, N.; Jin, M.; Stahley, M. R.; Stivers, J. T.; Zheng, Y. G. A transient
kinetic analysis of PRMT1 catalysis. Biochemistry 2011, 50, 7033–7044.
219. Chan-Penebre, E.; Kuplast, K. G.; Majer, C. R.; Boriack-Sjodin, P. A.; Wigle, T. J.;
Johnston, L. D.; Rioux, N.; Munchhof, M. J.; Jin, L.; Jacques, S. L.; West, K. A.;
Lingaraj, T.; Stickland, K.; Ribich, S. A.; Raimondi, A.; Scott, M. P.; Waters, N. J.;
Pollock, R. M.; Smith, J. J.; Barbash, O.; Pappalardi, M.; Ho, T. F.; Nurse, K.; Oza,
K. P.; Gallagher, K. T.; Kruger, R.; Moyer, M. P.; Copeland, R. A.; Chesworth, R.;
Duncan, K. W. A selective inhibitor of PRMT5 with in vivo and in vitro potency in
MCL models. Nat. Chem. Biol. 2015, 11, 432–437.

99

Appendix

Scheme A1. Synthesis of BM-45 1 a) piperidine, HOBt, DMF, rink amide resin, 2x10
min; Fmoc-Lys(alloc)-OH, HOBt, DIC, DMF, 12 hr; b) I2, ACCN, H2O, 48hr; c) MeI,
K2CO3, 18-crown-6, DMF, 12 hr; d) automated iterative synthesis, µW, Lys, Pro, 4hydroxyphenylacetic acid; e) trifluoroacetic acid, 2,2’-(ethylenedioxy)diethanethiol,
Triisopropylsilane, H2O, 4 hr.

Scheme A2. Synthesis of BM-26 1 a) automated iterative synthesis, µW, Arg, Lys,
Pro; b) piperidine, HOBt, DMF, rink amide resin, 2x10 min; c) benzyl chloride,
CS2CO3, DMF, 12 hr d) trifluoroacetic acid, 2,2’-(ethylenedioxy)diethanethiol,
Triisopropylsilane, H2O, 4 hr.
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Figure A1. MALDI-MS and ESI-TOF-MS characterization of all peptide inhibitors

116

Figure A2. MALDI-MS methylation inhibition assay for peptide inhibitor BM-47

Figure A3. MALDI-MS methylation inhibition assay for peptide inhibitor BM-11
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Figure A4. MALDI-MS methylation inhibition assay for peptide inhibitor BM-46

Figure A5. MALDI-MS methylation inhibition assay for peptide inhibitor BM-34
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Table A1. Kinetic data for peptide inhibitors

IC50 (µM)
Name

Structure

NTMT1

BM-1

>100

BM-2

>100

BM-3

>100

BM-4

>100

BM-5

>100

BM-6

>100

119

G9a

PRMT1

BM-7

>100

BM-8

>100

BM-9

33 ± 1.5

BM-10

>100

BM-11

2.7 ± 0.7

BM-12

>100

BM-13

>100

BM-14

>100

120

~70

>100

BM-15

>100

BM-16

>100

BM-17

>100

BM-18

>100

BM-19

>100

BM-20

>100

BM-21

>100

BM-22

>100
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BM-23

>100

BM-24

>100

BM-25

>100

BM-26

>100

BM-27

>100

BM-28

14 ± 2.5

BM-29

>100

BM-30

1.0 ± 0.13
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>100

>100

BM-31

4.8 ± 0.31

BM-32

4.5 ± 0.47

BM-33

>100

BM-34

4.3 ± 0.28

BM-35

>100

BM-36

12 ± 1.4
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>100

>100

BM-37

48 ± 2.0

BM-38

>100

BM-39

12 ± 2.9

BM-40

~80

BM-41

>100

BM-42

~80

BM-43

>100
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BM-44

~90

BM-45

~35

BM-46

4.2 ± 1.2

13 ± 4.1

>100

BM-47

0.32 ± 0.06

>100

>100
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Figure A6. IC50 curves of (A) BM-9; (B) BM-11, (C) BM-28; (D) BM-30; (E) BM-31; (F)
BM-32; (G) BM-34; (H) BM-36; (I) BM-37; (J) BM-39; (K) BM-42; (L) BM-46; (M) BM47
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Figure A7. Mass spectrum of (A) probes 1 (predicted m/z: 787.4137, detected m/z:
787.5989), (B) 2 (predicted m/z: 789.4366, detected m/z: 789.4373) and (C) 3
(predicted m/z: 930.4945, detected m/z: 930.4953).
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Figure A8. Mass spectrum of (A) probes 4 (predicted m/z: 1035.5304, detected m/z:
1035.5136), (B) 5 (predicted m/z: 817.4685, detected m/z: 817.4768) and (C) 6
(predicted m/z: 860.5219, detected m/z: 860.6093).
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Figure A9. MALDI-MS of probe 3 (predicted m/z: 930.4903, detected m/z: 930.4177)
(top). MALDI-MS of mixture of unmethylated (predicted m/z: 930.4903, detected m/z:
930.3553), mono- (predicted m/z: 944.5112, detected m/z:
944.3607), and
dimethylated (predicted m/z: 958.4503, detected m/z: 958.3816) photoaffinity probe 3
by NTMT1 in the presence of S-adenosyl methionine (SAM) after 15 minutes (bottom).
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Table A2. Michaelis-Menten constants for probes 1-3 and substrates RB1-10 and
SET1-10.

Table A3. Predicted and detected masses of peptide inhibitors and photoaffinity
probes

Compound

Predicted m/z

Detected m/z

BM-1

448.2555

448.2563

BM-2

503.3088

503.3101

BM-3

531.3150

531.3234

BM-4

454.3024

454.7672

BM-5

509.3558

509.8295

BM-6

537.3620

537.8239

BM-7

707.4563

707.4590

BM-8

462.2711

462.7081

BM-9

517.3245

517.7918

BM-10

545.3207

545.3402
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BM-11

701.4457

701.4629

BM-12

440.2868

440.2871

BM-13

495.3402

495.3469

BM-14

523.3463

523.3361

BM-15

693.4406

693.4441

BM-16

438.2711

438.2702

BM-17

493.3245

493.3200

BM-18

521.3307

521.3370

BM-19

677.4457

677.4526

BM-20

416.2404

416.2469

BM-21

471.3038

471.3032

BM-22

499.3099

499.3249

BM-23

402.2347

402.2354

BM-24

457.2881

457.2916

BM-25

485.2943

485.3022

BM-26

489.3296

489.3294

BM-27

434.2762

434.2785

BM-28

567.3402

567.3431

BM-29

512.2868

512.2907

BM-30

533.3194

533.3295

BM-31

478.2660

478.2631

BM-32

547.3351

547.3435

BM-33

492.2817

492.2858
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BM-34

532.3354

532.3393

BM-35

477.2820

477.2833

BM-36

546.3511

546.3712

BM-37

491.2976

491.2973

BM-38

532.3301

532.7223

BM-39

535.3193

535.7662

BM-40

547.3387

547.3602

BM-41

554.3128

554.8645

BM-42

568.3392

568.8913

BM-43

531.3365

531.9072

BM-44

377.2183

377.2165

BM-45

547.3608

547.3923

BM-46

533.3194

533.3492

BM-47

717.4406

717.5842

Probe 1

787.4137

757.5989

Probe 2

789.4366

789.4373

Probe 3

930.4945

940.4953

Probe 4

1035.5305

1035.5136

Probe 5

817.4685

817.4768

Probe 6

860.5219

860.6093

134

Vita
Brianna Danielle Mackie was born on September 14th, 1991 in Bitburg, Germany and is
an American citizen. She graduated from Grafton High School in Yorktown, Virginia in
2009. She received her Bachelor of Science in Chemical Engineering from Virginia
Polytechnic Institute and State University in Blacksburg, Virginia in 2013.

135

